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WNT/β-CATENIN MEDIATED CANCER STEM CELL ACTIVATION 
IN HEPATOCELLULAR CARCINOMA 
 
Harshulkumar M. Pandit 
July 26, 2018 
 
Hepatocellular carcinoma (HCC) is one of the deadliest cancers, with 
variable presentation, high chemotherapy resistance and early tumor recurrence.  
In this dissertation, we have systematically enriched, identified and characterized 
HCC cancer stem cells (CSCs) from 3 different HCC cell lines (Hepa1-6, HepG2, 
and Hep3B) using in vitro serum-free culture method. Enriched spheroids acquired 
CSC properties, primarily self-renewal capability, spheroid formation ability, and 
drug resistance. Heterogeneous CSCs enriched from Hepa1-6 cells demonstrated 
higher tumor initiation and proliferation capability in vivo, compared to control HCC 
cells in orthotopic immunocompetent mouse model.  
EpCAM+ CSCs were significantly enriched within heterogeneous Hepa1-6 
CSC spheroids. Consequently, we studied the fate of EpCAM+ CSCs in orthotopic 
immunocompetent mouse model with 3 different liver microenvironments i.e. 
control normal liver, steatosis (fatty liver induced), and nonalcoholic steatohepatitis 
(NASH). EpCAM+ CSC mediated HCC carcinogenesis was observed in NASH 
livers, but failed to develop in control and steatosis liver microenvironment. This is 
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the first study evaluating CSCs in immunocompetent mouse model and 
demonstrated the importance of liver microenvironment for EpCAM+ CSC 
mediated tumor initiation. We then performed a lineage tracking study by stably 
incorporating copGFP or mCherry in Hepa1-6 cells by lentivirus transduction, and 
examined the origin of tumors in NASH liver microenvironment using orthotopic 
C57L/J immunocompetent mouse model. Our findings suggest that tumor growth 
was dose dependent and most tumor nodules arose from copGFP expressing 
EpCAM+ CSCs.  
The Wnt/β-catenin pathway components were also found to be 
overexpressed in CSCs when compared to control. Human HCC specimen 
analyses suggested concomitant changes in β-catenin and EpCAM levels. Gene 
analyses of step-wise spheroid formation process identified possible 
dedifferentiation mechanisms regulated by β-catenin in CSC spheroids. Loss of 
function analysis by siRNA mediated transient knockdown of β-catenin confirmed 
its role in spheroid enrichment and doxorubicin resistance.  Canonical Wnt 
pathway study using chemical inhibitors identified β-catenin mediated CSC 
activation was regulated at nuclear level, and not at the cytoplasmic GSK3β 
destruction complex level. Analysis of human and mouse tumors suggested that 
constitutive activation of β-catenin transcription failed to respond to NOTUM, a 
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The most common primary liver cancer (80-90%) in the United States is 
Hepatocellular carcinoma (HCC) [1]. Also referred to as hepatoma, HCC is a type 
of epithelial cancer in liver, and one of the most common form of liver cancers in 
adults, age 50 or older. HCC is the fifth most common cancer in men and seventh 
in women worldwide, and accounts for the third major cause of cancer related 
deaths worldwide [2, 3]. Men are two to four times more likely to develop liver 
cancer than women. The development of HCC is closely associated with the 
presence of chronic liver disease, and therefore HCC remains a dynamic and 
challenging condition due to the dual effects from the malignancy and fragile liver 
function [3].  A 2013 CDC report has suggested that liver cancer related deaths in 
US men is increasing at the rate of 2% per year despite better success rates in 
other cancers [4]. HCC confers the highest death rate (~2.4%) and 2nd highest 
cancer incidence rate (~3.6%) amongst all cancers in United States [5]   (Figure 




Etiology of HCC 
Major known risk factors for HCC are cirrhosis, Hepatitis B virus (HBV) or 
Hepatitis C virus (HCV) infection, alcoholic liver disease, and non-alcoholic fatty 
liver disease (NAFLD) [3]. Newly added risk factors are obesity and type-II 
Diabetes for development of HCC [6, 7]. In HCC patients, distribution of these risk 
factors are highly variable, depending on ethnic groups and geographic regions [8]. 
Figure 1.1: Trends in HCC incidence and mortality in the US.  
Surveillance, Epidemiology, and End Result program (SEER) revealed liver 
cancer is challenging condition in US population. (Figure is adapted from 
the SEER website http://seer.cancer.gov/data/) 
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Most of these risk factors lead to cirrhosis or its progression, which is present in 
80-90% of HCC patients. According to a study by Fattovich et al., the 5 year 
cumulative risk for HCC development in cirrhosis patients ranges between 5% and 
30% globally, 18% in the United States, depending on cause, ethnic group, and 
stage of cirrhosis [9]. As a result of the variety of causes and risk factors for HCC, 
patients show vast diversity in clinical presentation and disease progression, 
compared to any other solid malignancies (Figure 1.2).  
Non-alcoholic fatty liver disease (NAFLD) and the rise in incidence of 
NASH-HCC  
Success of new direct-acting antiretroviral (DAA) therapy for Hepatitis C 
Virus (HCV) infection (the largest risk factor of HCC) has shifted recent 
epidemiology of cirrhosis and HCCs (Figure 1.3) [10, 11]. DAA also reduced liver 
transplant waitlist of patients with decompensated cirrhosis secondary to HCV by 
Figure 1.2:  Diversity in HCC diagnosis presentation, progression and 
tumorigenesis. Development of HCC is heterogeneous. After primary encounter 
with risk factor, liver inflammatory stage develops (chronic hepatitis) if not 
intervened, hepatitis eventually progressed further to non-reversible liver cirrhosis 
stage. Apx ~80% of HCC patients have cirrhosis history.    Figure is adapted from 
Levrero et.al. – Oncogene (2006). 
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32% compared with interferon treatment era, while simultaneously increased 
waitlist of patients in NASH by 41% [11].  
 
SEER-Medicare database study by Welzel et.al. reported that metabolic 
syndrome is significant risk factor in the United States [12]. American Society of 
Clinical Oncology (ASCO) reported that obesity will overtake tobacco as the 
leading cause of cancer in near future [13]. Around 1/3 of US population [14], and 
17% children and adolescents are considered obese [15]. Most comprehensive 
study in US population by Calle et.al. showed that liver cancer related death rates 
are correlated with body mass index [16]. Davila et.al. reported that Diabetes alone 
increases the risk of HCC by 2-3 fold, independent of presence of other risk factors 
of HCC [17]. A recent study by Kasmari et.al. reported that metabolic syndromes 
such as Diabetes and hypertension, are independent risk factors in development 
Figure 1.3:  Diagnosis distribution of HCV, alcohol liver disease (EtOH), and 
NASH in patients with HCC and chronic liver failure. (A) Incident diagnosis of HCC 
(B) Incident diagnosis of chronic liver failure.  Database: Healthcore 2006-2014. Figure 
is adapted from Goldberg et.al 2017. 
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of HCC in absence of Cirrhosis [18].  Most of these metabolic syndromes are also 
associated to NAFLD progression. 
In developed countries, increased incidence of HCC has been attributed to 
increase in incidence of NAFLD [10]. At least 25% of the US population has NAFLD, 
and NAFLD is becoming an epidemic [19, 20]. NAFLD is a range of chronic liver 
disease from steatosis (without inflammation) to NASH (inflammatory steatosis), 
and  NASH is the most severe form of NAFLD and present in 6% to 17% population, 
and a major source of cryptogenic cirrhosis [20].  It is predicted that NASH will 
constitute the most frequent cause of HCC and cirrhosis in developed countries in 
next decade [21].  
NASH patients without fibrosis are at lower risk of progressing to cirrhosis 
compared to advanced fibrosis , while progression to cirrhosis in NASH patients 
was reported to be 25% over 9 years [22]. NASH mediated HCC carcinogenesis 
can be either cirrhosis mediated or non-cirrhotic [21, 23]. Metabolic syndrome 
secondary to NASH is growing epidemic with higher risk associated with HCC 
carcinogenesis (Figure 1.4) [24]. Indeed, around 15% to 50% cases of NASH 
progresses to HCC without cirrhosis, confer a new challenge to clinicians and 
researchers to understand NASH mediated HCC progression [25].  Significant 
gaps remain to understand mechanisms by which NAFLD/NASH and its metabolic 




   
Treatment modalities, staging guidelines and prognostic assessment 
 
 
Figure 1.5:  Modified BCLC staging system and treatment strategies. Figure is 
adapted from the most recent EASL clinical practice guidelines (2018) 
Figure 1.4:  NASH is a growing HCC epidemic. Different stages and 
pathophysiology during progression of NASH. Figure is adapted and modified from 
the Allison et.al https://www.endocrinology.org/endocrinologist. 
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HCC has primarily two different growth patterns, and the most common 
growth pattern seen in the United States is development of HCC secondary to 
cirrhosis (chronic liver damage), where HCC typically starts as several small 
cancer nodules at multiple sites in the liver, referred as global growth pattern 
(global hepatic damage). Diagnostic presentation of global HCC tumor growth in 
most cases considered as non-qualifying criteria for tumor resection (the best 
treatment modality available with the highest disease free and overall survival).  
The other growth pattern widely observed is single HCC tumor which grows larger 
and later spreading to neighboring regions in the liver. This single HCC tumor 
growth pattern, in most cases, qualifies for tumor resection and thus offers a better 
prognostic outcome.   
HCC prognosis and treatment modalities are not considered solely based 
on HCC tumor growth pattern, but rather follow systemic guidelines.  Barcelona 
Clinic Liver Cancer (BCLC) staging system [26] (Figure 1.5), and Child-Pugh 
cirrhosis classification system are the two most widely practiced HCC 
staging/treatment guidelines to determine HCC prognosis and primary tumor 
treatment options for HCC patients  [27, 28]. The BCLC staging guidelines are 
based primarily on radiological images, and do NOT consider HCC grade or other 
known risk factors. After following staging criteria, if patient’s tumor is categorized 
as “Resectable” then surgical resection (ideal treatment option with the best overall 
survival and outcome) or liver transplantation is considered. If staging criteria 
categorize HCC as “Unresectable” then palliative treatment options are considered, 
i.e. local thermal ablation, Local Regional Therapies (LRTs)  such as trans-arterial 
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drug eluting beads (loaded with Doxorubicin) (TACE-DEB) and Radioembolization 
(Y-90 beads), targeted molecular therapy (Sorafenib – multikinase inhibitor, 
Regorafanib), or immunotherapy (Nivolumab).  
Prognosis and disease free survival are subjective to individual patient’s 
HCC stage, hepatic synthetic function, and implementation of treatment options.  
HCC treatment with systemic therapy, local regional therapies (LRTs), or surgery 
have been marginally successful because a substantial subpopulation of HCC 
cells defined as cancer stem cells (CSCs), which fail to respond to treatment and 
contribute to minimal residual disease (MRD) [29] and thus a very short 
remission time of disease free interval.   
 
CANCER STEM CELLS 
 
Cancer Stem Cell (CSC) Model and HCC:  
Discovery of cancer stem cells (CSC) or tumor initiating cells (TIC) has 
changed our view of carcinogenesis 
and chemoresistance [30, 31]. 
Understanding that tumor 
development and growth is not only 
maintained by selection of 
genetically mutated population of 
cells (stochastic model), but also by 
the tumor microenvironment which 
facilitates communication between 
Figure 1.6:  Cancer stem cell model: 
Cancer stem cell model can explain 




altered tumor cells and their unaltered neighbors like fibroblasts, endothelial cells, 
and inflammatory cells [32]. CSCs are a small population of less differentiated cells 
within the tumor microenvironment which possess stem cell like properties i.e. self-
renewal capability and ability to differentiate into heterogeneous lineages of cancer 
cells via asymmetric division [30]. CSC model proposes hierarchical organization, 
where apex CSC retains self-renewal capability with the highest tumorigenic 
potential (Figure 1.6), while the well differentiated cancer cells lose this important 
stemness property and become less tumorigenic [30, 33]. Lapidot et al. proposed 
the CSC hypothesis for the first time in primary human acute myeloid leukemias 
(AMLs) in 1994 [34]. A study on breast cancer by Al-Hajj et al. was the first to report 
evidence of CSCs in solid tumors [35]. Since then, several studies have reported 
presence of CSCs in solid tumors like colon [36], pancreas [37], and liver [38-40]. 
The first direct evidence to support CSC theory came from lineage-tracing study 
by Barker et al. in 2007, where they studied tracing of lgr5+ cells in development 
of small intestine and colon tumors in genetically engineered mice [41]. In 2012, 
two more groups had published lineage-tracing studies in genetically engineered 
mouse models [42, 43].  
Several groups have studied role of CSCs in HCC and reported their clinical 
significance [44, 45]. The CSC tumor model has been proven to show clinical 
relevance in primary HCC and HCC recurrence [45-47]. Haraguchi et al. identified 
a subset of stem cells, “side population” (SP) cells, in Huh-7 and Hep3B cell lines 
which highly express multi-drug resistant ABC-transporters [48]. Ma et.al. and 
colleagues have shown that sorted SP cells possess high expression of stemness 
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genes and higher tumorigenicity [46, 47]. Using tumorigenicity potential and 
stemness characteristics as CSC markers, many studies have identified CSCs 
from human HCC tissues and HCC cell lines expressing the following stem cell 
markers - EpCAM+, CD90+, CD44+, CD133+, AFP+, OV6+, and ALDH1+ [45, 47, 
49, 50]. These diverse surface markers on CSCs have been thought to be a result 
of  heterogeneity of tumor microenvironment, and no single surface marker can 
define HCC CSCs exclusively [51].  
 
CSCs contribute to treatment failure 
In HCC, studies have identified EpCAM+ cells in tumors of patients, and 
showed that these EpCAM+ cells correlate with worse prognosis and possess 
CSC-like properties which showed tumor initiating capabilities in as few as 200 
cells in a nude mouse model [38, 50, 52-54].  Recurrence of HCC after definitive 
tumor treatment occurs in over 70% of patients within 14 months of initial treatment. 
MRD is responsible for poor prognosis and early tumor recurrence in HCC. Clinical 
studies have shown that recurrent HCC tumors exhibit resistance to chemotherapy 
treatments and attain aggressive tumor growth [47]. CSCs are resistant to 
chemotherapeutics and considered as the primary players for tumor relapse and 
metastasis in HCC [55-57].  Importantly, a multi-drug resistant transporter ABCG2, 
a well characterized CSC functional marker, has been implicated for doxorubicin 
resistance in multiple studies [48, 58-61]. Many recurrent HCC cases have a 
different biology than the primary index tumor. These recurrent tumors account for 
most therapeutic failures and eventually result in the death of patients.  The 
11 
 
molecular mechanism underlying chemotherapy resistance and tumor recurrence 
in HCC is not yet clear.  
 
Wnt/β-catenin signaling, CSCs, and HCC: 
Canonical Wnt/β-catenin signaling pathway regulates several cellular 
events including cell proliferation, and is considered a fundamental pathway in 
stem cell biology [62]. It is one of the most extensively studied molecular signaling 
pathways in HCC and CSCs [62]. In the absence of Wnt ligand, β-catenin is bound 
to the complex of APC, Axin, and GSK-3β (termed degradation complex), and is 
phosphorylated and targeted for ubiquitin mediated degradation. β-catenin also 
exists in a cadherin-bound form and regulates cell–cell adhesion. When Wnt binds 
to frizzled receptor (Fz) and Lrp5/6 (LDL receptor family protein 5/6) on the cell 
membrane, the GSK-3β (non-
phosphorylated, active state) is 
phosphorylated at the Ser-9 position 
(inactive state). β-catenin is uncoupled and 
is stabilized following inactivation of GSK-
3β, and the stabilized β-catenin 
translocates to the nucleus, where it 
activates target genes by binding to 
TCF/LET transcription factors. 
Many reports have demonstrated 
the role of the Wnt/β-catenin signaling in 
Figure 1.7:  Canonical Wnt/β-
catenin pathway: Canonical Wnt 
pathway required Wnt ligand 
binding on receptor, for stabilizing 
β-catenin and its translocation into 
nucleus. Figure source: Nature. 
2005 Apr 14; 434 (7035):843-50. 
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tumorigenic CSCs [62]. EpCAM is one of the important CSC markers, and is a 
target of Wnt/β-catenin signaling. The inhibition of the Wnt/β-catenin signaling has 
been shown to destroy EpCAM-positive cells [54, 56]. Studies have reported the 
role of Wnt/β-catenin signaling in self-renewal and maintenance of CSCs in HCC 
[63, 64]. Also, ABCG2, a functional CSC marker, was suggested to be regulated 
by β-catenin in CSCs and contributes to drug resistance [59, 60, 65].  
 
Challenges in treatment outcome assessment for HCC 
The current response criteria do not accurately assess HCC treatment 
response to more advanced modalities like Sorafenib (multikinase inhibitor), and 
Local Regional Treatments (LRTs) such as TACE-DEB beads, and Y-90 beads 
[66, 67]. Traditional Response Evaluation Criteria in Solid Tumors (RECIST) was 
designed for assessing chemotherapeutic agents, which are cytotoxic for rapidly 
dividing cancer cells, and measure reduction in tumor size. Therefore, standard 
tumor size criteria cannot accurately assess advanced treatment modalities which 
were developed in past two decades (LRTs and Sorafenib), locally targeted or 
targeting molecular pathways. Hence, tumor response to these new treatment 
modalities can also be assessed by analyzing tumor vascularity reduction, 
changes in metabolic activity, and tumor cell apoptosis and necrosis [68, 69].  
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Traditional response criteria (WHO and RECIST) may not accurately 
assess the response to LRTs and Sorafenib, because these criteria do not 
evaluate tumor necrosis and/or tumor vascularity reduction. After LRTs or 
Sorafenib, the tumor size may remain the same or sometimes increase. The 
increase in the size of a tumor (due to necrosis, hemorrhage, or edema) and 
decrease in vascularity can be explained by the responding effect of tumors [70] 
(usually interpreted as necrosis as shown in Figure 1.8, [71]). Because of these 
limitations of WHO and RESIST criteria (not designed to assess viable tumors but 
reduction in tumor size), a modified RESIST criteria was formally introduced in 
2008 by AASLD (American Association for the Study of Liver Disease), defined as 
mRESIST [72].  The mRESIST criteria 
incorporated the concept of viable tumor 
introduced by EASL (European 
Association for the Study of the Liver) [73]. 
Two independed studies found that 
objective response calculated by EASL 
criteria were higher than traditional 
RESIST criteria [74, 75]. (The majority of 
this subsection is adapted from Singh et.al. 
2014 [71]). 
However, most radiologists are 
neither familiar nor comfortable with this 
type of radiologic assessment.  Similarly, 
Figure 1.8: LRT response 
evaluation. Pre-treatment (2a and 2b) 
and 4 week follow-up (2c and 2d) scans 
by arterial phase CT after TACE-DEB. 
Treatment by TACE-DEB demonstrates 
an increase in tumor size (2c and 2d) 
but more than 80% of its volume is 
necrotic with the only viable tumor seen 
as a nodular enhancing area along its 
inferomedial margin. This qualifies as 
a favorable response to treatment 
despite of the increase in tumor size. 
Image source: Singh et.al. 2014.  
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there remains no increase in payment for these types of radiologic reads which are 
both challenging and far more time consuming that standard reads.  Until a “quality 
of CT and MRI” reads exist there will remain high variability in assessing tumor 
response in all unresectable therapies for HCC.  Suboptimal assessment of HCC 
treatment outcome could miss early detection of HCC tumor recurrence, often 
contributed by activation of CSCs within minimal residual disease and miss the 
window of opportunity for early intervention.  
 
Significance and research direction of this dissertation: 
 Published studies have shown increasing evidence that support the role of 
CSCs in HCC carcinogenesis, chemotherapy resistance and tumor recurrence. 
There is a compelling need to connect and better define these isolated findings for 
translational and clinical relevance. Importantly, well-reported CSC surface 
markers EpCAM, CD44, and CSC functional marker ABCG2 have been reported 
as targets of Wnt/β-catenin signaling, and also have been implicated in 
development of chemotherapy resistance and HCC prognosis [58, 76, 77]. 
However, origin and activation of CSCs in HCC is not yet been well defined. A 
mouse model overexpressing wild-type or mutant β-catenin failed to initiate HCC 
[62]. These data suggest that not much is known about initial molecular events 
triggering activation of Wnt/β-catenin signaling in HCC.  
 
HCC Cells       ??         Wnt/β-catenin trigger      CSC Activation     




In this dissertation, we sought to understand the role of Wnt/β-catenin 
pathway in HCC CSC activation and development of chemotherapy resistance.  
We hypothesize that “In HCC, the Wnt/β-catenin mediated CSC enrichment is 
responsible for acquiring chemotherapy resistance and therapeutic failure”.  
We grow CSC spheroids without mechanical induction (or low adherent 
plates) using regular tissue culture plates. This allowed the pursuit of the goal, 
which is to identify and characterize CSCs enriched spontaneously in laboratory 
setting, and then methodically study role of Wnt/β-catenin in CSC activation 
(Chapter 3).  
EpCAM, the most characterized and well accepted CSC marker is 
associated with poor prognosis in patients [53] and is a target of the Wnt/ β-catenin 
pathway. For the first time, we evaluated EpCAM+ CSCs from 3 different HCC cell 
lines in immunocompetent and immunocompromised mouse models with 
orthotopic implants (Chapter 4).   
Following in vivo study, we sought to identify accountable triggering events 












MATERIALS AND EXPERIMENTAL METHODS 
 
2.1) Cell lines 
Hepatoma cell lines, Hepa1-6 (CRL-1830), Hep3B (HB-8064) and HepG2 
(HB-8065), were obtained from American Type Culture Collection (ATCC, 
Manassas, USA). All cell lines were validated every six months or obtained from a 
new ATCC stock every 6 months. All experiments were performed between 5th 
and 20th passage. 
Hepa1-6 was reported as a non-immunogenic murine cell line with an ability 
to form tumors in normal immunocompetent C57L/J mice, both orthotopically and 
subcutaneously [78-80], thus provide more clinically relevant mouse model to 
study tumorigenesis in presence of all confounding immune system components, 
contrary to athymic nude or SCID mouse models (lacks confounding immune 
system components). HepG2 and Hep3B secrete 17 major plasma proteins [81], 
and also express high EpCAM levels, a well reported CSC marker [38].   
2.2) Cell culture and spheroid formation:    
Hepa1-6 and Hep3B cells were grown in DMEM (MediaTech, Corning, Cat 
#  10-013-CV) with 4.5% Glucose, supplemented with 10% FBS (Sigma, Cat # 
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F2442), 100 IU/mL Penicillin, 100 µg/mL Streptomycin, 0.25 µg/mL  Amphotericin 
(Antibiotic and Antimycotic, MediaTech Corning, Cat # 30-004-CI), 10 µg/mL 
Tylosin (Antimycotic, Sigma, Cat # T3397).  HepG2 cells were grown in Minimum 
Essential Media (MEM, Gibco, Cat # 11095-080), supplemented with 10% FBS 
(Sigma, Cat # F2442), Non Essential Amino Acids (Gibco, Cat # 11140-050), 
Sodium Pyruvate (Gibco, Cat # 11360-070), 100 IU/mL Penicillin, 100 ug/mL 
Streptomycin, 0.25 µg/mL  Amphotericin (Antibiotic and Antimycotic, MediaTech 
Corning, Cat # 30-004-CI), 10 µg/mL Tylosin (Antimycotic, Sigma, Cat # T3397).   
For in vitro enrichment of Cancer Stem Cells (CSCs), we employed a widely 
used and accepted spheroid formation assay. Hepa1-6, HepG2, and Hep3B cells 
were grown in a serum-free condition (SF Group) in DMEM/F12 (1:1) media 
(SIGMA, Cat # D6434), supplemented with 2 mM L-Glutamine (SIGMA, Cat # 
G7513), 20 ng/mL recombinant human Epidermal Growth Factor (EGF, Sigma, 
Cat # E9644 ), and 10 ng/mL recombinant human basic Fibroblast Growth Factor 
(bFGF, Sigma, Cat # F0291 ), 100 IU/mL Penicillin, 100 ug/mL Streptomycin, 0.25 
µg/mL  Amphotericin (Antibiotic and Antimycotic, MediaTech Corning, Cat # 30-
004-CI), 10 µg/mL Tylosin (Antimycotic, Sigma, Cat # T3397).  
2.3) Self-renewal assay: 
Hepa1-6 cells were seeded in serum-free (SF) media at a density of 2000 
cells/well in 6-well plate, and incubated for 4 days to allow the development of 
speroids. After confirming formation of spheroids under the microscope, these 
spheroid population of cells were collected in 15 mL centrifuge tube, treated with 
trypsin-EDTA for 4 minutes, and prepared single-cell suspension with 500 cells/mL 
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density with SF media. Seed single cell suspension at 2 uL/well in 96 well plate. 
Mark the wells with one or two cells. Add 150 uL SF media in each marked well 
and monitor for 20 days. Images were taken on a daily basis to track progress.  
2.4) Cell proliferation assay: 
Cell proliferation was measured using the MTT assay (3-(4,5-dimthyl-
thiazol-2-yl)-2,5 diphenyltetrazolium bromide) in a 96 well format. Hepa1-6 cells 
were seeded in triplicates at a density of 3000 cells/well in complete media (control 
group) or serum-free media (SF group) and incubated overnight. A separate plate 
was prepared for each time-point (0, 24, 48, 72, and 96 hours). After appropriate 
incubation period, MTT was added in each well at the final concentration of 0.5 
mg/mL, and plate was incubated for 3 hours at 37 °C in CO2 incubator. After MTT 
incubation, media was removed from each well and 100 uL DMSO was added to 
dissolve formazon crystals which generate violet color. Absorbance was measured 
with plate reader at 540 nm with appropriate controls in each plate. For analysis, 
we considered the shorter incubation time MTT reading (overnight) as 0 hour and 
set it as control for the subsequent time points.    
2.5) Doxorubicin (Adriamycin) resistance assay:  
Hepatoma cells (Hepa1-6, HepG2, and Hep3B) were seeded at a density 
of 5000 cells/well in a 96 well plate in triplicates, with one set of control group 
(complete media) and two sets of spheroids group (serum-free media). Separate 
96 well plates were seeded for different time points (24, 48, 72 and 96 hours) 
simultaneously on the day of seeding. After 24 hours, serum-free media is replaced 
with complete media in one of the two sets of spheroids group (termed as SFR, 
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reserum) and incubated for another 24 hours. On the day 3, media is replaced with 
complete or serum-free media containing different concentrations of Doxorubicin 
(0.05 µM, 0.5 µM (clinical), and 5 µM (10x clinical)) (SIGMA, Cat # D1515). MTT 
assay was performed at 24, 48, 72, and 96 hours after initiating DOX treatments 
as described in the cell proliferation assay.  Each plate and group had appropriate 
untreated control in triplicates, and corresponding data for untreated group was 
considered as 1 i.e. 100 % viability. DOX treated cells were normalized to their 
corresponding untreated controls on the same plate, compared and analyzed.   
2.6) Flow cytometry analysis:  
Hepa1-6 control or 7 day spheroid cells grown in 100 mm discs were 
collected by gentle cell scraping. Collected cells were passed through 50 micron 
strainer 5 times to remove cell clumps, followed by repeat pipetting for 10-20 times 
to obtain single cell suspension. Use of trypsin was avoided to preserve integrity 
of surface receptors. Cell numbers were counted and single cell suspension was 
verified using a Hemocytometer.  Each sample was transferred to a 15 mL tube 
and centrifuged for 5 minutes at 300 RCF to obtain cell pellet. Cell pellets were 
washed 2 times with 2% BSA/PBS. Pellets were resuspended in 100 uL 2% 
BSA/PBS and transferred into 1.5 mL microfuge tubes. Corresponding unstained 
and single stained controls were seperated for each sample, 106 cells/100 uL. 
FITC, APC or PE conjugated primary antibodies were added in 100 uL of cell 
suspension as per manufacturer recommendations or in-house optimized dilution 
(1:100 for most experiments and antibodies).  Samples are gently vortexed and 
incuabted in the dark at 4 °C for 1 hour. After incubation, cells were washed once 
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with 1 mL 2%BSA/PBS, resuspended in 500 uL 2% BSA/PBS, transferred into 
labeled flow-tubes, and stored in the dark on ice until analysis were performed. 
Data were recorded on BD FACSCanto or BD FACSCalibur (BD Biosciences). For 
analysis, live cells were gated to exclude dead cells and cell debris.  Required 
compensations were performed for dual FITC and PE staining experiments. In 
majority of our experiments, we chose FITC and APC. Data analysis was 
performed either by FACS Diva or FlowJo software suites. 
2.7) Immunocytochemistry (ICC) staining:  
Hepa1-6 control or spheroid cells were grown in 8 well Nunc™ Lab-Tek-II 
chamber slide (Thermo scientific, Cat # 154534) for 7 days (seeded at 100 
cells/well to avoid overgrowth at the end of 7 days). Media was changed on the 4th 
day to ensure viability.  Cells were fixed with 4% PFA for 30 minutes (or 70% 
ethanol overnight). Fixed cells were washed 2 times for 15 minutes with PBS-T,  
and blocked with 10% BSA in PBS for 20 minutes. Blocked cells were washed 
again for 2 times for 15 minutes with PBS-T and incubated with 100 uL primary 
FITC conjugated antibodies at room temprature for 2 hours (EpCAM, CD90, 
CD133, 1:100 dilution in 10% FBS in PBS-T). Following antibody incubation, cells 
were given 3 time 10 minute PBS-T washes and stained for nuclear staining with 
DAPI (1:1000 dilution).  After DAPI staining, cells were given 2 time 10 minute 
PBS-T washes. Plastic chambers were removed from each Lab-Tek slides as per 
manufacterur’s instructions, using the tools provided. The exposed glassslide 
surface with cells were sealed with coverslip using 5-10% glycerin. The slides were 
then examined using  Olympus 1×51 microscope at 20x magnification using the 
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Olympus DP72 digital camera via the cellSens Dimention imaging system 
(Olympus, Pittsburgh, PA) with FITC, DAPI and brightfield settings. Digital images 
were taken, and analyzed using Cellsense software (Olympus, Pittsburgh, PA).  
2.8) Aldefluor assay for ALDH activity: 
Aldefluor activity was assayed in Hepa1-6 control and spheroid cells using 
Aldefluor kit according to the manufacturer’s instructions (Stemcell technologies, 
Canada). Briefly, 3 mL of cell suspension was prepared in DMEM without serum 
at 106 cells/mL final dilution. These cells were centrifuged at 250 RCF for 5 minutes, 
and pelleted cells were resuspended in 3 mL of Aldefluor buffer on ice. To get the 
fluorescence product, we added 45 uL of Aldefluore substrate into 3 mL of the 
each of the cell suspension samples on ice. Immediately after mixing, 1 mL was 
transferred into a new tube containing 30 uL ALDH1 inhibitor 
diethylaminobenzaldehyde (DEAB), and later used as an inhibitor control (negative 
control). Test samples and negative controls were incubated at 37 °C for 45 
minutes, mixed every 10 minutes. Then, cells were cenrifuged at 250 RCF for 5 
minutes, resuspended in Aldefluore buffer and incubated on ice for 1 hour. Data 
were recorded on BD FACSCanto at FITC channel with 488 excitation laser. 
2.9) Hoechst 33342 efflux assay: 
After 7 days in culture, Hepa1-6 Control and spheroid cells were harvested 
in 15 mL centrifuge tubes. 5 mL cell suspension with 106 cells/mL was prepared 
for each sample, centrifuged at 250 RCF for 5 minutes, washed two times and 
resuspended in 2%FBS in PBS. Hoechst 33342 (Life technologeis, Cat # H1399) 
dye was added to 5 mg/mL final concentration in 2% FBS in PBS and cells were 
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incubated for 90 minutes at 37 °C. Cells were then incubated on ice for 10 minutes, 
followed by ice cold 1X PBS wash. These cells were immediately mounted on 
glass slides and analyzed within 1 hour on a fluorescence microscope with UV 
excitation settings. It is imperative that cells were viable during the steps of the 
assay. Hoechst 33342 dye stains the nuclear compartment  and is visible at 355 
nm excitation (blue color) using the common DAPI filter. Cells with dye exclusion 
property were identified by comparing/overlaping the images obtained under 
brightfield settings.  
2.10) Lentivirus transduction and generation of stable HCC cell lines: 
We used commercially available fourth generation lentivirus packing system 
(Lenti-X, Takara-Clontech), for generating stable cell lines. Briefly, puromycin 
resistant – copGFP (pLenti-CMV-GFP-Puro) and Blasticidin resistant mCherry 
(pLV-Bsd-CMV-mCherry) vectors were obtained and amplified in Stable 
competent EColi (New England Biolabs) by employing standard molecular biology 
protocol with 100 µg/mL Ampicillin selection, purified for lentivirus packing using 
commercial plasmid prep kit (Takara-Clontech). For generating lentivirus, lenti-X 
reagent was mixed with 6 µg of lentivirus plasmid and transfected in 293T cell line 
(Takara-Clontech) for packing.  Harvested lentivirus were used to transduce target 
cell lines using polybrene with established protocol. Hepa1-6, HepG2, and Hep3B 
cell lines were transduced with copGFP lentivirus, and cell lines were selected with 
3 µg/mL puromycin (Sigma-Aldrich) and expanded after confirmation by 
fluorescence microscope for copGFP expression.  Hepa1-6 cell line was 
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transduced with mCherry lentivirus, and selected with 10 µg/mL Blasticidine 
(Sigma-Aldrich).  
 
2.11) B-Mode ultrasound imaging 
Linear-mode ultrasound data was generated and recorded using a 
VisualSonics 2100 high-frequency ultrasound system with MS-400 probe (30 MHz 
center frequency) and the VisualSonics 3D acquisition imaging hardware and 
software.  To exclude noise caused by movement from respiratory and cardiac 
function, we acquired data using software-based respiratory and cardiac gating. 
Cardiac and respiration gating can synchronize data acquisition at defined time 
within the cardiac cycle and/or only acquire data when the animal is not actively 
breathing, thus allowing limiting movement artifact and high quality images.  The 
entire liver was scanned in B-mode image using the 3D motor and Vevo2100 
software.  To stay consistent with animals and images, we have stored our settings 
on the instrument.  Stored setting parameters: Frame rate = 16, depth = 12.00 mm, 
dynamic range = 65 dB, width = 15.36 mm. The optimal ROI plane was selected 
following B mode analysis of 3D liver data to allow us maximum liver plane 
coverage, as well as to learn organ orientation avoiding vessels/organs in that ROI 
plane.   
2.12) Preparation of animals for imaging and contrast agent preparation 
After 10 weeks on special diets, animals were evaluated by high-frequency 
ultrasound (VisualSonics model 2100, Toronto, Canada). The animal was 
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positioned on a heated platform under 1.5% isoflurane anesthesia.  Abdominal fur 
corresponding to the liver was removed by a depilatory cream. The animal’s body 
temperature, heart rate, and breathing were continuously monitored during the 
entire imaging procedure.   
Shortly before each experiment, lyophilized Vevo MicroMarker non-targeted 
contrast agent (VS-11913, VisualSonics, Canada) was prepared to generate an 
injection-ready contrast agent.  Briefly, we resuspended sterile 700-µL saline in 
each VS-11913 vial using a 1-mL syringe and 21G 5/8” needle.   This stock solution 
(2 x 109 microbubbles/mL) was further diluted to 1:10 in saline for each animal 5 
minutes before injection (2 x 108 microbubbles/mL). 100 µL of this diluted contrast-
agent (2 x 107 microbubbles) was administered as a bolus injection via tail-vein 
method for data acquisition.  
 
2.13) Contrast-enhanced ultrasound (CEUS) imaging 
Contrast-enhanced imaging was performed using the MS-250 (22 MHz) 
probe. We used non-linear mode ultrasound for this application. We used a tail-
vein for contrast injection using a standard technique.  Briefly, the tail was 
submerged in warm water (35 – 45°C) for 1 minute to dilate lateral veins and then 
cleaned with 70% ethanol.  We attached a syringe containing 100 µL contrast-
agent (VS-11912 cannulation kit, VisualSonics, Canada) to PU tubing and a 27G 
butterfly needle and confirmed the absence of air bubbles.  We then confirmed 
ultrasound site location, probe orientation, and instrument settings. The optimal 
ROI plane was selected following B mode analysis of 3D liver data to allow us 
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optimal liver plane coverage by avoiding vessels/organs in that ROI plane. ROI 
was defined manually using measurement tools of VevoCQ software.   After 
confirming all experimental settings, we recorded pre-bolus perfusion data and 
then injected 100 µL of prepared contrast agent while continuing contrast-
ultrasound data acquisition.  To stay consistent between animals and images, we 
have stored our acquisition settings on the same instrument.  Stored setting 
parameters: Frame rate = 25, depth = 12.00 mm, dynamic range = 65 dB, width = 
23.04 mm.  
2.14) Ultrasound data analysis 
Acquired data was stored without editing and one copy was transferred to 
an analysis workstation. B mode quantification was carried out by calculating mean 
gray-scale intensity of three hepatic ROIs for each animal using pixels v/s intensity 
histogram, and averaged within a group.  B-mode renal cortex mean gray-scale 
intensity was calculated for each animal, and averaged within a group. 
Hepatic/renal ratio was calculated as “mean gray-scale intensity of the liver/mean 
gray-scale intensity of the renal cortex” for each group.  
Perfusion-quantification data analysis was carried out using the Vevo CQ 
software module (VisualSonics, Toronto, Canada).  Briefly, for each animal data 
time point, captured contrast-enhanced ultrasound clips were analyzed 
independently in three steps. In the first step, the clip-editor module was used for 
inclusion-exclusion of frames/images to ensure data quality. We excluded any 
frame(s) that were not aligned with the rest of the frames due to gross motion 
artifact. In the second step, additional fine motion correction was used for 
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additional movement compensation by spatially realigning successive images to 
minimize respiratory background. In the third step, the quantification module was 
used to perform quantitative analysis of contrast-agent perfusion in regions of 
interest. Linear/pre-log data were analyzed for the time intensity curve analysis 
using VevoCQ software module. The software module uses curve-fitting 
algorithms based on a mathematical model of bolus-kinetics.   
 
2.15) Animal experiments  
Sexually matured 8-week-old C57L/J mice (stock # 000668, both male and 
female) and Nu/J (stock # 002019, males only) were purchased from Jackson 
laboratory.  All animal studies were carried out in strict compliance with the 
Institutional Animal Care and Use Committee (IACUC) guidelines at the University 
of Louisville. All experimental procedures were approved by the IACUC at the 
University of Louisville (UofL). All mice were housed in the UofL Research 
Resources Center (RRC) at 22°C with 12-hour light/dark cycles with free access 
to food and water. 
In vivo experiments using the Hepa1-6 cell line (control v/s spheroids) were 
performed in 12-week-old male C57L/J mice (inbred at UofL).  Each experimental 
group had n=6 animals. For orthotopic inoculation, 2x106 Hepa1-6 non-spheroid 
control cells or 7-day spheroids were injected into left liver lobe of an animal. Post 
injection, mice were monitored for two weeks and then euthanized on day 14. 




Establishing diet induced animal models (chapter 4)  
Sexually matured 8-week-old C57L/J mice were inbred to develop 
consistent and accurate diet-induced mouse models necessary for this study.  
After 1 month from the birth on normal chew diet, mice were randomly assigned to 
one of three groups (n=6 mice/group).  Then each group was assigned to one of 
the three diets and mice were fed a normal control diet (10% fat, D12450B, 
Research Diets, Inc., New Brunswick, NJ), or high-fat diet (60% fat, D12492, 
Research Diets, Inc., New Brunswick, NJ), or NASH diet (choline deficient diet with 
0.1% methionine and 60% fat) for next 10 weeks. For orthotopic inoculation, 2x106 
sorted EpCAM+ or EpCAM- Hepa1-6 cells were injected into left liver lobe of an 
animal. Post injection, mice were monitored for 18 days by high-frequency 
ultrasound to follow the tumor growth and euthanized on day 18. Animal weight, 
liver weight, tumor weight, and tumor size were recorded for each animal. 
Establishing Nu/J orthotopic mouse models (for HepG2 and Hep3B studies in 
chapter 4)  
8-10 week-old male Nu/J mice (purchased from Jackson laboratory) were 
used for both HepG2 and Hep3B in vivo experiments.  For orthotopic inoculation, 
2x106 sorted EpCAM-Low or EpCAM-High cells (HepG2 or Hep3B) were injected 
into left liver lobe of an animal. Post injection, mice were monitored for 70 days by 
high frequency ultrasound for tumor growth monitoring, and then euthanized on 
day 70. Animal weight, liver weight, tumor weight, and tumor size were recorded 




2.16) Protein extraction and Western Blot analysis:   
After treating cells with respective media and/or regulators for desired time, 
media was aspirated from the culture and cells were washed two times with 1X 
PBS. Cells were lysed by adding SDS lysis buffer (supplemented with protease 
and phophatase inhibitors, Thermo scientific, Cat # 78443) directly into wells (100 
uL per well of 6-well plate or 500 uL per 100 mm plate). For spheroids group (non-
adharent cells), cells were collected by gentle scraping and pipetted into 15 mL 
centrifuge tube. Culture media was removed by centrifugation for 5 mins at 150 
RCF to collect cells followed by two time 1x PBS washes to remove all media 
traces. Lysis buffer was then added into the tube according to pelleted packed cell 
volume (100 uL lysis buffer for each 20 uL packed cell volume). Cells were 
transfered to 1.5 mL microfuge tube and sonicated for 10-15 seconds on ice. After 
30 minutes incubation on ice, lysates were centrifuged for 30 minutes at 14,000 
RCF at 4 °C. Supernatant containing total cellular protein was collected carefully 
and transfered to new labeled 1.5 mL microfuge tube.  Purified protein samples 
were stored at -80 °C untill further use. For cytoplasmic and nuclear fractionation, 
we used a commercially available kit (Pierce, ThermoFisher, Cat # 78833). 
Fractionation was performed as per manufacturer’s protocol. Extracted protein 
were stored at -80 °C untill further use. 
Extracted protein were quantified using the Bradford assay (Biorad, Cat # 
500-0006) in a 96 well plate format and readings were performed at 620 nm using 
the ELISA reader (MultiSKAN MCC/340, Thermo Scientific).  
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Equal protein (20-50 µg each) were loaded on 8% SDS-PAGE 
electrophoresis gel. Protein samples were seperated by SDS-PAGE  and then 
electrotransferred onto nitrocellulose membrane (Amersham, GE) . Following 
electrotransfer, the membane was blocked in 5% non-fat milk for 1 hour at room 
temprature. The membrane were incubated in primary antibody overnight (1:1000 
or 1:2000 final dilution). Next day, the membrane was washed 3 times with TBST 
for 7 minutes each. The membrane was then incubated for 1 hour in secondary 
HRP conjugated-Anti-Mouse IgG (Cell Signaling, Cat # 7076; OR Santacruz 
Biotech, Cat # sc-2005) or secondary HRP conjugated-Anti-Rabbit IgG (Call 
Signaling, Cat # 7074; OR Santacruz Biotech, Cat # sc-2004 ). Secondary 
antibodies were diluted either 1:2000 or 1:4000 as per experimental requirement. 
Ater secondary antibody, blot was washed 3 times by TBST, followed by 1 wash 
of TBS and incubated in dark for 1 minute in Westen Blot Luminol Reagent 
(Santacruz Biotech, Cat # sc-2048).  Chemiluminescence signals were detected 
in the darkroom using x-ray films. Densitometry analysis were conducted using 
ImageJ software (NIH).  
Primary antibodies:  β-Catenin (SantaCruz Biotech, Cat # sc-7963), β-actin 
(SantaCruz Biotech, Cat # sc-81178) , GAPDH (SantaCruz Biotech, Cat # sc-
365062), GSK3β (Cell Signaling, Cat # 9832), phospho-GSK3β (Ser-9) (Cell 
Signaling, Cat # 5558), ABCG2 (Cell Signaling, Cat # 4477), Cyclin-D1 (Cell 
Signalling, Cat # 2978), TCF-1 (Cell Signaling, Cat # 2203), C-MYC (Cell Signaling, 




2.17) RNA interference (siRNA) and Spheroid Reversibility Assay:  
For each siRNA used, we provided sense and antisense sequences in table 
– 2.1. Lipofectamin RNAiMAX, and validated siRNA oligos targeting β-catenin 
(siCtnnb1: s63417, s63418; and siCTNNB1: s436, s437) or scrambled control (Cat 
# 4390849) were obtained (Lifetechnologies, CA, USA) and experiment was 
performed as per instructions provided. Cells were seeded and allowed to grow 
spheroids for 3-4 days, transfected on 4th day with siRNAs, and incubated for 
additional 72 hours (Hepa1-6) or 48 hours (HepG2). For calculating CSCs, 
differentiated, and single cells, 5 random fields/well were selected and quantified. 
Data were normalized to untransfected control, followed by mean and S.D. 
calculation. Experiments were performed n=3 times independently, and 
transfection was carried out using combination of two siRNAs targeting different 
exons.  
 





Sequence (5’ -> 3’) Length 
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2.18) Human HCC specimens: 
This study was approved by the Institutional Review Board for Human Study 
at University of Louisville. The study samples were retrospectively collected from 
24 patients who had undergone liver resection for hepatocellular carcinoma 
between 2002 and 2013. 24 subjects, 13 male (54.2%) and 11 female (45.8%) with 
a median age of 67, ranging from 41 to 84 years old, who had a clinical diagnosis 
of hepatocellular carcinoma and underwent liver resection, were studied. The 
control samples consisted of the same 24 patients’ normal adjacent tissue that 
were within the resected liver specimen.   
 
2.19) Hematoxylin and Eosin (H&E) staining 
 After animals were euthanized, liver tissues were isolated and weighted. A 
piece of tissue was taken from a liver lob and fixed in 10% buffered formalin for 24 
hours and transferred to 80% ethanol.  The formalin-fixed liver tissue was 
processed (stepwise dehydrated) and embedded in paraffin.  Serial 5-µm sections 
were mounted onto glass slides. These slides were used for Hematoxylin and 
Eosin (H&E) staining for each animal.  HE staining was blinded and analyzed by 
two pathologists for experimental groups and assign total NAFLD histopathology 
score (0-8) based on inflammation (0-3), steatosis (0-3), and Hepatocyte 




2.20) Immunohistochemical assay for EpCAM in human specimens: 
EpCAM protein expression were determined by using an 
immunohistochemical assay. Staining was carried out on the paraffin-embedded 
tissues using the DAKO EnVisionTM+System kit (DAKO Corporation, Carpinteria, 
CA) according to the manufacturer’s instructions. The sections were deparaffinized 
and hydrated, then the slides were washed with TRIS buffer.  Peroxidase blocking 
was performed for 5 minutes. After rewashing, the slides were incubated with 
EpCAM antibody (1:100) (SantaCruz Biotechnology Inc, CA) for 30 minutes at 
room temperature.  The slides were rinsed and the specimens were incubated with 
the labeled polymer for 30 minutes at room temperature.  Then, the chromogenic 
substrate diaminobenzidine was added as a visualization reagent.  Finally, the 
slides were counterstained with methyl green for EpCAM.  A negative control was 
included in each run. 
2.21) Computer image analysis of IHC:  
A computer image analysis was performed to quantify the expression of 
EpCAM in the 24 samples diagnosed with HCC, and in the 24 samples of adjacent 
normal liver (AD).  The imaging fields were chosen randomly from various section 
levels to ensure objectivity of sampling. Five imaging fields were scanned for each 
specimen sample.  All digital images were acquired with the Olympus i×51 
microscope at 40x magnification using the Olympus DP72 digital camera via the 
cellSens Dimention imaging system (Olympus, Pittsburgh, PA) and stored as JPG 
data files with fixed resolutions of 200 pixels/inch.  The acquired color images from 
the immunohistochemical staining were defined at a standard threshold according 
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to the software specification.  The computer program then quantified the threshold 
area represented by color images.  EpCAM protein expression was defined by the 
percentages of threshold area in acquired color images. 
 
2.22) Statistical analysis:  
Appropriate statistical methods were referenced in each dataset or 
experiment throughout this dissertation. Primarily, data are presented as 
mean±S.D. or mean±SEM (n ≥ 3 per group). Comparison statistics were performed 
by two-tail student’s t-test with equal variance or one way analysis of variance 
(ANOVA). All the statistical analysis were performed (including chart, plots etc.) 
using either Sigmaplot statistical software or microsoft excel 2013. Results with 














In this first chapter, we characterized 3 HCC cell lines to study properties of 
CSCs. Hepa1-6 is murine cell line, and HepG2 and Hep3B are human HCC cell 
lines.  
Serum-free conditions plus growth factors allow cells to grow in an 
anchorage-independent manner, and is a well-documented standard method for 
maintaining undifferentiated cells [84-87]. This technique is widely adapted for 
CSC studies in breast cancer [88] and glioblastoma [89]. Soon after, this technique 
was accepted and used in many other solid tumor malignancies including 
hepatocellular carcinoma [47, 90].  Also known as spheroid formation (sphere 
formation) culture, this is not only a CSC property, but also serves as a valuable 
tool to enrich CSC-like cells in vitro. Spheroids formed in serum-free culture have 
been suggested to mimic not only the phenotype but also the genotype of the 
primary tumor [89]. In fact, serum-free culture has been accepted and used for in 
vitro enrichment of CSCs [91].  
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A recent study reported that generating multicellular spheres followed by 
reversal to the attached cell line can significantly change the cell phenotype, which 
can be used as in vitro metastatic model [85]. Therefore, spheroid cultures provide 
a useful approach to enrich CSCs and to study CSC-like cells present in primary 
tumors with the added advantage of reproducibility and validity of findings. One 
study previously reported that not all cell lines can enrich CSC-like cells in spheroid 
culture, and each cancer cell line should be evaluated carefully and subjectively 
[92].  
Unlike the previous studies in which CSC spheroids were enriched in low-
attachment plates or mechanically induced [91], we used regular tissue culture-
treated plates. Using adherent environment could resemble the in vivo 
microenvironment to a certain extent (metastasis migration via EMT by detaching 
site of primary tumor organ) [93].  
Studies have reported the role of Wnt/β-catenin signaling in self-renewal 
and maintenance of CSCs in HCC [63, 64], and two of the most reported CSC 
markers in HCC, EpCAM and CD44, have been identified as the transcription 
targets of the canonical Wnt/β-catenin pathway [38, 94, 95]. Therefore, we studied 
status of Wnt/β-catenin signaling in enriched culture of HCC CSCs. Also, for the 
first time, we evaluated tumorigenic property of Hepa1-6 CSCs in 






3.1) Hepatoma cells could form anchorage-independent, self-renewing 
spheroids (spheres) in serum-free culture in vitro: 
To enrich HCC CSCs from hepatoma cell lines in vitro, we employed serum-
free conditions using DMEM/F-12 (1:1) media supplemented with recombinant 
human Epidermal Growth Factor (EGF) and basic Fibroblast Growth Factor 
(bFGF). We evaluated spheroids for CSC properties. We found that all three 
hepatoma cell lines (Hepa1-6, HepG2, Hep3B) successfully formed spheroids in 
serum-free conditions (Figure 3.1).  
Self-renewal capability is the most fundamental property of CSCs and 
proposed as the primary mechanism responsible for maintaining undifferentiated 
cells with CSC like properties in tumors [96]. We have primarily characterized 
Hepa1-6 spheroids.  To test if enriched Hepa1-6 spheroids possess self-renewal 
capability, we performed two separate experiments. In the first experiment, we 
tested if spheroid cells can be serially passed from one generation to the next 
without dying or losing spheroid forming capability.  The rationale behind this 
experiment is to show that well differentiated cells cannot survive in serum-free 
stress conditions optimized for anchorage independent growth, while only cells 
with stem-like properties are able to maintain themselves and propagate. Hepa1-
6 spheroids were serially passaged for more than 10 generations in serum-free 
conditions, indicating their self-renewal capability (data not shown).  
In the second experiment, we confirmed self-renewal capability of CSC like 
cells by means of more quantitative “self-renewal assay”.  Hepa1-6 spheroid cells 
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were seeded in 96 well plates (single cell/well) and monitored for their growth 
pattern daily for 20 days (Figure 3.2). In this condition, cells can have one of three 
fates: 1) self-renewal (spheroid formation), 2) differentiation (adherent phenotype), 
3) quiescence (stays as a single cell). Approximately, 24% Hepa1-6 cells showed 
self-renewal capability by forming spheroids. These growing spheroids (Figure 3.2 
- A & C) also expressed EpCAM (CSC marker), further supporting CSC like-
properties of spheroids.  Around 51% cells stayed in the quiescence state, while 
about 25% cells lost their stem-ness and proceeded to differentiation (Figure 3.2 - 
D).   
We also performed an MTT assay to quantitate cell proliferation rates in 
Hepa1-6 control and spheroid cells.  We have found that Hepa1-6 spheroids 
retained proliferative capability, but growth rate is significantly slower than parental 













Figure 3.1:  Representative images of cultured cells. Bright field microscope 
images. (A) Control hepatoma cells and (B) CSC Spheroids (Serum-free /SF 
group) in Hepa1-6, HepG2, and Hep3B cell lines.  4x (Bar = 500 µm), 10x (Bar = 


































































































































































































































































































Figure 3.3:  Hepa1-6 Spheroids retained proliferative capabilities. MTT Assay was 
performed in 96 well plate, with seeding 3000 cells/well in triplicates.  CSC spheroids 
retained proliferative capabilities in serum-free media, but exhibit slower growth rate 
compared to control group cells (complete media with serum).  n= 3 independent 
experiments. Values shown as mean±SD. 
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3.2) HCC spheroids acquired doxorubicin resistance– a first line chemotherapy 
drug in HCC 
Resistance to chemotherapeutics is another important characteristic of 
CSCs, and is believed to play a significant role in HCC carcinogenesis and 
recurrence [44]. Currently, doxorubicin (Adriamycin, DOX) is a first line drug used 
for HCC treatment in clinics [3].  
We studied Hepa1-6 spheroids for their DOX resistance property with MTT 
assay as described in materials and methods.  For in vitro experiments, we 
selected a clinical relevant dose (0.5 µM) as characterized in early 
pharmacokinetic studies in patients and widely employed by other groups for DOX 
studies [97].  We have also tested 1/10 (0.1x, 0.05 µM) and 10 times (10x, 5 µM) 
doses for characterization. Time dependent dose response curves have 
demonstrated that Hepa1-6 CSC spheroids were sensitive to DOX at early time 
points but developed resistance 48 hours post DOX treatment at both subclinical 
and clinical doses (Figure 3.4). We found that for the 10x dose (5 µM) there were 
a fraction of cells that retained higher viability after 72 hours.  
When we further analyzed our data by plotting log (DOX dose) v/s viability 
at 96 hour time point, we found that Hepa1-6 spheroids required 2 times more DOX 
compared to control cells to eradicate 50% viable cells (Figure 3.5-A).  Hepa1-6 
spheroids were seen to have significantly increased chemotherapy resistance for 
doxorubicin at not only physiologically relevant dose of 0.5 µM but also to 10-fold 
dose increase (5 µM) (p<0.005) (Figure 3.5-B). 
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We have also investigated HepG2 and Hep3B spheroids for their DOX 
resistance properties. After 96 hours of treatment, both HepG2 and Hep3B CSC 
spheroids showed significant higher resistance for DOX compared to control cells 
at clinical dose of 0.5 µM (p<0.05) (Figure 3.6). These data support our results 

























































































































































































































































































































































































































Control 0.05 µM 0.5 µM 5 µM
C 1.00 ± 0.0 0.61 ± 0.02 0.27 ± 0.04 0.03 ± 0.01
SF 1.00 ± 0.0 0.66 ± 0.04 0.45 ± 0.07 0.09 ± 0.03
SFR 1.00 ± 0.0 0.57 ± 0.09 0.32 ± 0.06 0.03 ± 0.02
Doxorubicin (ADR) Resistance ‐ MTT Assay  ( Hepa1‐6 Cells)
Doxorubicin Treated (Concentrations) 
A
Figure 3.5: Hepa1-6 spheroids exhibit doxorubicin resistance. Value 1 on y-axis 
represents 100% cell viability. (A) Dose dependent response curve (Log [Dox] v/s Cell 
viability) after 96 hours of Doxorubicin treatment. Hepa1-6 spheroids required increased 
Doxorubicin dose (2 times higher than C, and 4 times higher than SFR) to eradicate 50% 
cells.  (B) Hepa1-6 spheroids (SF) are more resistant to Doxorubicin compared to control(C). 
n=3 independent experiments, values shown in “Mean ± S.D”, *(p<0.05), NS=No 






Figure 3.6.  Human HepG2 and Hep3B spheroids showed doxorubicin resistance 
property, supporting findings in mouse Hepa1-6 cells. HepG2 or Hep3B cells were 
seeded in 96 well plate in triplicates at 3000 cells/well and studied for their chemotherapy 
resistance properties by MTT assay. Value 1 on Y-axis represents 100% cell viability. (A) 
doxorubicin resistance in HepG2 cells. (B) Doxorubicin resistance in Hep3B cells. For both 
human cell lines, HepG2 and Hep3B, spheroids showed higher resistance to doxorubicin 
compared to corresponding controls. Values represent mean±S.D, *(p<0.05), NS=No 
significance (p>0.05). C= Control group, SF= Serum-free group, SFR= Re-serum group.    
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3.3) Enriched HCC spheroids showed higher expressions of cancer stem cells 
(CSCs) surface markers and functional markers: 
Surface and functional markers are currently the best available tools to 
define the origin and lineage of cells in animal tissues, and therefore, these tools 
are extensively employed to characterize CSCs in solid malignancies including 
HCC [31, 51, 98].  Most extensively characterized and reported surface markers 
for HCC CSCs are EpCAM, CD90, CD44, AFP, OV6, and CD133 [47, 51, 99].  It 
is noteworthy that EpCAM+ and CD90+ cells are physiologically different in terms 
of their tumorigenic potential and differentiation stage [54], and so is true for other 
markers. Because of a high degree of heterogeneity, no single maker could 
confidently and exclusively define HCC CSCs. Extensive research is being done 
globally in this pursuit. 
In order to confirm CSC-like properties in HCC spheroids, we selected 
extensively reported and studied surface markers i.e. EpCAM, CD90, CD44, and 
CD133, and tested HCC spheroids for their expression by flow-cytometry and ICC.  
Our findings suggest that HCC spheroids showed upregulation in EpCAM levels 
compared to control, and EpCAM+ cells are enriched in spheroid culture (Figure 
3.7-A). We confirmed our findings with ICC using anti-EpCAM antibodies (Figure 
3.7-B).  We also confirmed upregulation of CD90, CD44, and CD133 in spheroid 
culture with enrichment of CD90+, CD44+, CD90+/CD44+, and CD133+ cells 
(Figure 3.8).  Each of these subpopulations bears different physiological properties 
and differentiation states e.g. CD44+/CD90+ cells were suggested as more 
tumorigenic and less differentiated compared to CD44+/CD90- or CD44-/CD90+ 
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cells alone [51].  Our findings confirmed that in vitro Hepa1-6 spheroids can enrich 
all important CSC subpopulations reported so far. 
As it is defined by its asymmetric cell division property and hierarchical 
importance, the CSC theory is a functional concept. Two extensively reported 
functional markers to define CSCs, ALDH activity and Hoechst 33342 efflux assays 
[48, 100], were also tested in Hepa1-6 CSC spheroids. Hepa1-6 spheroids showed 
1.3% increase in ALDH+ cells (Figure 3.9-A). Spheroid cells also showed property 
of dye exclusion (Figure 3.9-B), which was confirmed by Western Blot analysis of 
ABCG2, multi-drug resistant transporter responsible for dye exclusion (Figure 3.9-
C). Dye efflux depends on expression and activity of ABCG2, and clinically 







Figure 3.7:  Hepa1-6 spheroids showed increased EpCAM expression. Hepa1-6 cells 
were grown in serum-free media (spheroids) or control media for 7 days. After 7 day 
treatment, cells were harvested and analyzed for EpCAM expression. (A) EpCAM 
expression analysis by flow-cytometry using APC conjugated Anti-EpCAM antibodies, 
**(p<0.005), n=4 independent experiments, (B) EpCAM expression analysis by ICC using 
FITC conjugated Anti-EpCAM antibodies. 7 Day SF treatment. Cells were fixed, stained and 







Figure 3.8:  Hepa1-6 spheroids also showed increased CD44, CD90 and CD133 
expression, well reported CSC surface markers. Hepa1-6 cells were grown in 
serum-free media (spheroids) or control media for 7 days. After 7 day treatment, cells 
were harvested and analyzed for corresponding markers. (A) CD44 and CD90 
expression analysis by flow-cytometry, and CD90 analysis by ICC. (B) CD133 expression 
analysis by flow cytometry and ICC. Cells were fixed, stained and analyzed by 







   
Visible 355 nm (UV) Merged 
Figure 3.9:  Hepa1-6 spheroids showed increased CSC functional markers. 
Hepa1-6 cells were grown in serum-free media (spheroids) or control media for 7 days. 
After 7-day treatment, cells were harvested and analyzed. (A) Aldefluore assay showing 
higher ALDH enzyme activity in CSC spheroids compared to control. (B) Hoechst 33342 
efflux assay - ICC representative images of spheroids showing dye efflux, contributed by 
ABCG2 activity. Stem-like cells with high ABCG2 activity show less staining compared 
to normal cells (low ABCG2 activity). ICC at 10x magnification (Bar = 200 µm). Hoechst 
33342 stains nuclei. (C) Representative Western Blot and densitometry analysis of 
ABCG2 expression. Increased ABCG2 expression in spheroids compared to control. 






3.4) Upregulation of β-catenin in hepatocellular carcinoma CSC spheroids:  
Many signaling pathways are implicated and studied in CSCs [101]. Wnt/β-
catenin pathway is the cardinal pathway in normal stem cell maintenance and 
highly implicated in HCC and CSCs [62, 102].  
Enriched Hepa1-6 CSCs showed increased β-catenin protein levels both in 
the cytoplasm (1.53±0.21 fold, p<0.05) as well as in nucleus (1.54±0.15 fold, 
p<0.001) compared to control cells (Figure 3.10-A). We also tested β-catenin 
levels in HepG2 cells and found it to be consistent with our findings in Hepa1-6 
cells (data not shown). Total RNA analysis by qRT-PCR further confirmed the 
increased β-catenin and stemness in Hepa1-6 spheroids viz. significant increase 
in both EpCAM and Lin28B mRNA expression (figure 3.10-B).  
To further confirm functional consequences of higher β-catenin levels in 
Hepa1-6 CSC spheroids, β-catenin downstream targets (C-MYC, Cyclin-D1, LEF1) 
were analyzed by Western Blot analysis. All three downstream targets we tested 
were proportionately increased with increased β-catenin levels (Figure 3.11), 
suggesting that higher β-catenin levels in CSC spheroids have functional 
consequences. More importantly, C-MYC and Cyclin-D1 are strongly implicated in 
carcinogenesis [32].  
To further investigate the increase in β-catenin levels, we tested GSK-3β 
phosphorylation status. Active GSK-3β (no Ser9 phosphorylation) directs 
cytoplasmic β-catenin to ubiquitin mediated proteasomal degradation by 
phosphorylating β-catenin at S33/S37/T41 positions. However, when GSK-3β 
itself is phosphorylated at Ser9 position, it loses its substrate specificity for β-
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catenin and cytoplasmic β-catenin gets stabilized, translocates to the nucleus and 
regulates transcription at the gene level. Hepa1-6 CSC spheroids showed increase 
in inactive GSK-3β levels (phosphorylated at Ser9) compared to control cells 
(Figure 3.12). This finding suggests that GSK-3β activity at least partially 
contributed to increased β-catenin levels in Hepa1-6 spheroids and needs to be 















Figure 3.10:  Hepa1-6 spheroids showed increased β-catenin levels. Hepa1-6 cells 
were grown for 7 days in serum-free media (SF) or complete media (control). Cells were 
harvested after 7-day treatment, and cytoplasmic and nuclear proteins were extracted.  (A) 
Representative Western Blot (left), and densitometry image analysis (right). * (p≤0.05), 
**(p≤0.005), n=3 independent experiments. Lamin A/C and α-tubulin were used for 
fractionation control for nuclear and cytoplasmic fractions respectively. β-actin used as 
loading control and for normalization. Cyto = Cytoplasm; Nuc = Nuclear; C=Control; 
SF=Serum-free. (B) qRT-PCR analysis of total RNA for EpCAM, β-catenin and Lin28B 







Figure 3.11: Hepa1-6 spheroids showed increased expression of β-catenin 
downstream targets. Hepa1-6 cells were grown for 7 days in serum-free media (SF) or 
complete media (control). Cells were harvested after 7-day treatment, and total proteins 
were extracted using SDS buffer. All three β-catenin downstream targets i.e. TCF-1, C-MYC, 
and Cyclin-D1, were found to be increased in CSC spheroids compared to control. (A) 
Representative Western Blot, (B) Densitometry image analysis. β-actin used as loading 






Figure 3.12:  Higher β-catenin levels in Hepa1-6 spheroids may be contributed via 
GSK-3β activity. Hepa1-6 cells were grown for 7 days in serum-free media (SF) or complete 
media (control). Cells were harvested after 7 day treatment, and total proteins were extracted 
using SDS buffer. No change was observed in total GSK-3β levels, but phosphorylated GSK-
3β (Ser9) levels were increased in CSC spheroids compared to control. (A) Representative 
Western Blot, (B) Densitometry image analysis. **(p≤0.005), n=3 independent experiments. 
β-actin used as loading control. C=Control; SF=Serum-free. 
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3.5) HCC CSC spheroids are more tumorigenic in vivo:  
We used an orthotopic C57L/J mouse model to further test tumorigenic 
potential of Hepa1-6 spheroids where CSCs were being enriched [80]. Hepa1-6 
cell line possess tumorigenic property in immunocompetent C57L/J mice [78, 79]. 
Seven-day cultured 2x106 cells from Hepa1-6 spheroids as well as non-spheroid 
control cells were inoculated into upper left lobe of livers of 12-week-old 
immunocompetent C57L/J mice (n=6 mice/group) and monitored for two weeks.  
Mice injected with Hepa1-6 spheroids developed more aggressive tumors with 
overall higher tumor volume (6593±2615 mm3) compared with mice injected with 
control cells (1388±968 mm3; p≤0.05, n=6) (figure 3.13-C). Also, Hepa1-6 
spheroids developed more aggressive tumors with significant higher tumor weight 
(3.1±1 g) compared with mice injected with control cells (1.1±0.5 g; p≤0.05, n=6) 
(figure 3.13-C). The aggressive growth pattern of CSC tumors was also witnessed 
by multiple HCC nodules found at different lobe sites within the liver compared to 
control, suggesting that CSC spheroids possess increased tumor initiation and 
hepatic invasive capabilities (figure 3.13-A). These findings were confirmed by 
H&E staining (Figure 3.13-B). Increased liver weight was also observed in the 
spheroid group (3.26±1.2 g) compared with the control group (1.77±0.9 g, NS, n=6), 
which is likely due to aggressive growth and higher tumor mass in the spheroid 
injected group. This justifies the increased overall body weight by about 3g in the 






Figure 3.13: CSC spheroids demonstrated higher tumorigenic capability. 12 
week old C57L/J mice were injected with 2x106 control hepa1-6 cells or Hepa1-6 
spheroids (n=6 mice/group) into left liver lobe. Tumors were allowed to grow for two 
weeks and mice were euthanized at the end of two weeks; (A) Representative liver 
tumors of control and spheroid group mice; (B) Representative HE staining of control 
group and spheroid group, bright field images with 10x magnification (upper, bar = 200 
µm) and 40x magnification (lower, bar=50 µm); (C) Quantitative comparison of body 
weights, liver weights, tumor weights, and tumor volumes between control and 




In the current work, we have successfully identified HCC cells with CSC-
like properties in hepatoma cell lines using in vitro spheroid culture. These CSCs 
are poorly differentiated, and possess all defined CSC properties i.e. self-renewal, 
proliferation, and chemotherapy resistance. Surface markers analysis (EpCAM, 
CD90, CD44, and CD133) and functional marker analysis (ALDH and Hoechst 
efflux assays) further confirmed enrichment of CSCs, especially EpCAM+ CSC 
cells. Analyzing Wnt/β-catenin pathway components in CSCs showed up-
regulation of β-catenin expression, which is most likely a result of changes in GSK-
3β phosphorylation.  Preliminary in vivo data in the mouse models support that 
spheroid forming CSCs show significant higher tumor proliferation rate compared 






















EFFECT OF LIVER MICROENVIRONMENT ON FATE OF EPCAM+ CSCS IN 
ORTHOTOPIC ANIMAL MODELS 
 
Introduction: 
EpCAM possess prognostic value in HCC patients and is correlated with 
worse prognosis [53]. EpCAM is also a proposed target of the canonical Wnt/β-
catenin pathway [95, 103]. As identified in the Chapter 3, EpCAM expression is 
significantly increased in the CSC spheroids compared to adherent control Hepa1-
6 cell line.  Therefore, the aim of this chapter was to systematically evaluate 
EpCAM expressing CSCs in a comprehensive in vivo study. 
 In order to initiate tumor in humans, tumor initiating cells (including 
CSCs) must overcome destruction events coordinated by host immune defense 
[104]. Thus, it is inaccurate to define CSCs by merely studying in vitro criteria such 
as self-renewal, drug-resistance, heterogeneity, and tumor initiation ability with 
lower cell numbers in immunocompromised mouse models, because these 
approach often ignores rate limiting immunological factors. Limited research in 
CSC have been attempted to understand immunological properties of CSCs [105-
107]. Recent findings in tumor immunology and check-point inhibitors confirmed 
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that tumor microenvironment serve as key confounding factor dictating tumor 
growth or response to therapeutics [32, 108]. 
 HCC carcinogenic progression is a multistep process which follows 
the pathogenic sequence of repeated liver damage (Figure – 1.1). Cirrhosis and 
NASH are the two most reported liver microenvironment influencing HCC 
development [109]. Previous studies had attempted to evaluate the property of 
CSCs in immunocompromised mouse model with hind limb xenograft [110]. 
However, hind limb xenograft approaches lack the liver microenvironment and also 
ignore the role of immunological factors observed in HCC patients, and hence are 
not clinically relevant. None of the previous CSC studies have examined tumor 
initiation properties of CSCs in orthotropic animal models of HCC. 
  Here, for the first time, we have systematically evaluated the fate of 
three EpCAM expressing HCC cell lines (i.e. Hepa1-6, Hep3B, and HepG2) in 
orthotopic animal models of HCC, in different immunocompetent liver 
microenvironments (Hepa1-6), as well as xenograft immunocompromised models 










4.1) Non-alcoholic steatohepatitis promotes EpCAM positive cancer stem cells 
mediated tumorigenesis in immunocompetent mouse model of HCC  
Establishing orthotopic immunocompetent mouse models with 3 different liver 
microenvironment:  
To study the carcinogenic biology of EpcAM+ and EpCAM- CSCs in 
immunocompetent mouse model of HCC, we established 3 diet induced animal 
models developing three different liver microenvironments.    
As shown in figure 4.1-A, clear differences in gross liver appearance and 
H&E histology were observed for progressive non-alcoholic fatty liver disease 
(NAFLD) developed in each of the three animal models. In early steatosis (HFD 
group), the hepatocytes present small fat vacuoles in the vicinity of the 
endoplasmic reticulum (liposomes) – showing microvesicular fatty change. The 
size of the vacuoles increase during disease development, and push the nucleus 
to the periphery of the cell, showing macrovesicular fatty change. In steatohepatitis 
(NASH group), steatosis with inflammation and ballooning can be seen, which is 
the hallmark of hepatocellular damages in steatohepatitis. Ballooning is 
characterized by cellular swelling, extreme decrease in hepatocytic cytoplasm and 
clumped strands of intermediate filaments. Control group mice displayed normal 
healthy liver pathology. NAFLD hepatopathology scores calculated from H&E 
histology (Figure 4.2 - A and B), confirmed inflammatory microenvironment 
development in NASH group of animals (6.6±0.22, n=10), compared to control 
(0.625±0.183, n=8) and HFD (2.5±0.267, n=8).   
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We also analyzed plasma alanine transaminase activity (ALT, U/L, indicator 
of liver damage and liver disease progression). ALT activity in NASH group 
animals was significantly higher compared to control and HFD animals (Control: 
105.6±15.6, HFD: 143.75±10.3, NASH: 667.6±62.4, n=4/group, ##p<0.005, n=4, 
error bar = SD) (Figure 4.1 -C). Liver Triglycerides (TG, mg/dL/mg liver) levels 
were highest in NASH group animals compared to Control and HFD animals 
(Control: 8.73±2.11, HFD: 20.73±4.52, NASH: 30.48±4.66, n=4/group, *p<0.05, 
n=4, error bar = SD) (Figure 4.1-D).  
We followed all animals for 16 weeks to monitor weight gain over the time. 
In patients, NASH developed as a result of fatty liver progression and so overall 
weight gain is observed. However, animal model studies found NASH 
development with methionine and choline deficient diet (MCD) alone resulted in 
significant weight loss in the first month after switching the diets. Therefore, for our 
study, NASH group animals were fed with modified MCD diet containing 60% Kcal 
fat with 0.1% methionine. This modified MCD diet does not result into significant 
weight loss.  Control and NASH diet animals gained similar weight as showed in 
figure 4.2-A.  This made our NASH animal model more clinically relevant because 
NASH pathology developed in mostly obese patients suffering with fatty liver 
without weight loss. After 18 weeks, we have euthanized animals and recorded 
body weight, liver weight, and liver/body ratio (%) as reported in figure 4.2-B.  
Consistent with other studies and in patients, significant higher liver/body ratio 
percentage were found in NASH animals compared to control and HFD (Control: 
63 
 
4.47±0.48, HFD: 4.90±0.34, NASH: 7.63±0.49, n=4/group, **p<0.005 error bar = 
SD).  
To study underlying liver vascularity changes, we employed the high-
frequency contrast enhanced ultrasound (CEUS) methodology (manuscript is 
under communication at the time of this dissertation). CEUS demonstrated more 
sensitive determination of diffused liver diseases including underlying changes in 
vascularity, in patients with NAFLD and HCC [111, 112]. We have successfully 
developed a methodology to track the NAFLD progression non-invasively based 
on study by Cocciolillo et at. 2014 using air-filled contrast agent.  Vascularity of 
liver parenchyma is one of the key pathological factors affected by fatty infiltration 
and steatohepatitis development. Non-targeted contrast agent used in CEUS to 
confirm tumor diagnosis provides a very sensitive tool to capture vascular 
differences, and can be exploited for early diagnosis of fatty infiltration and 
steatohepatitis.  Therefore, we have subjected our 3 experimental mouse models, 
representing different stages of fatty liver disease progression, to CEUS imaging 
with an aim to investigate potential application in diagnosis. We have used bolus 
perfusion model to record, analyze, and compare the data. The step-by-step 
experimental procedure and data analysis is described under Methods section 
(Chapter 2).  
As shown in figure 4.3-A, peak enhancement (PE, representing blood flow, 
a.u.) was significantly deceased in the HFD group, and lowest in the NASH group 
compared with the Control group (Control: 37.4±2.3, HFD: 24.7±2.7, NASH: 
14.8±2.7; p<0.001, n=6/group).  Wash-in rate (WiR) found to be significantly 
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deceased in HFD group, and lowest in NASH group compared to Control group 
(Control: 6.6±0.44, HFD: 5.03±0.70, NASH: 1.90±0.20; p<0.001, n=6/group) 
(Figure 4.3-B). Another vascular parameter, wash-in perfusion index (WiPI = 
WiAUC (Area under the curve (wash-in))/RT (Rise time), WiPI is representative of 
blood flow), was also found to be significantly decreased in HFD, and lowest in the 
NASH group compared with Control (Control: 24.58±1.3, HFD: 16.28±1.85, NASH: 
9.9±1.98; p<0.001, n=6/group) (Figure 4.3-C).   PE and WiPI independently 
confirmed that NASH liver parenchyma exhibited the lowest blood flow, which 
could be due to severe fatty infiltration.  Pearson correlation analysis as showed in 
respective lower panels of figure 4.3-C, found that PE, WiP, and WiPI significantly 
correlate with hepatopathology scores (showed in figure 4.1-B).   
Altogether, we have successfully established 3 different diet induced mouse 
models representing three distinct liver parenchyma pathology, correlating with 
HCC development. After 10 weeks on special diets, control diet animals developed 
normal liver parenchyma, HFD animals developed mild steatosis, and NASH diet 
animals developed steatohepatitis condition with severe steatosis and 
inflammation (Figure 4.1-A).   After successful development of animal models, we 
proceeded to test tumorigenic ability of EpCAM+ and EpCAM- Hepa1-6 cells 
(stably expressing copGFP) in these 3 distinct liver microenvironments and 















Figure  4.1:  Establishing diet induced animal models – liver pathology. Animal 
experimental groups. (A) Representative images of whole liver and corresponding HE 
staining. 10X magnification (Bar = 200 µm); (B) HE staining was analyzed and assign 
total NAFLD hepatopathology score (0-8), based on inflammation (0-3), steatosis (0-3), 
and hepatocyte ballooning (0-2) features for each specimen. error bar = SEM, Control: 
control diet animals (n=8), HFD: high fat diet animals (n=8), NASH: NASH diet animals 
(n=10); (C) Plasma ALT activity (## p<0.005, n=4, error bar = SD); (D) Liver triglycerides 
















Figure  4.2:  Establishing diet induced animal models. Animal were followed for 16 
weeks. (A) Animal whole body weight changes over the time (error bars = SD); Control 
diet animals (n=8), High fat diet animals (n=8), NASH diet animals (n=10); (B) Animals 
euthanized at the end of 18 weeks. Comparison table for body weight and liver weight 









Figure 4.3:  CEUS can identify loss of vascularity with fatty liver progression. 
CEUS was performed with tail vein intravenous injection of non-targeted contrast agent 
and data were captured for bolus perfusion kinetics. Data was analyzed by VevoCQ 
software.  A: Peak enhancement (PE) found to be significantly deceased in HFD group, 
and lowest in NASH group compared with Control group (Control: 37.4±2.3, HFD: 
24.7±2.7, NASH: 14.8±2.7; p<0.001, n=6/group). B: Wash-in rate (WiR) found to be 
significantly deceased in HFD group, and lowest in NASH group compared with Control 
group (Control: 6.6±0.44, HFD: 5.03±0.70, NASH: 1.90±0.20; p<0.001, n=6/group).   C: 
Wash-in perfusion index (WiPI) was found to be significantly decreased in HFD, and 
lowest in NASH group compared with Control (Control: 24.58±1.3, HFD: 16.28±v1.85, 
NASH: 9.9±1.98; p<0.001, n=6/group).  Lower panels showed Pearson correlation 
analysis with Hepatophatology scores and found to be significant (p<0.05) for all 3 
contrast parameters i.e. PE, WiP, and WiPI. (showed on graphs, R=Pearson 
coefficient, p=significance value).   
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NASH microenvironment promotes EpCAM+ CSCs mediated tumorigenesis in 
immunocompetent microenvironment. 
We hypothesize that “immunocompetent liver microenvironment affects 
tumorigenesis of EpCAM+ CSCs”. To test our hypothesis, we established 3 
orthotopic immunocompetent HCC models and studied the oncogenic effect of 
EpCAM+ HCC CSCs.  
Hepa1-6 is non-immunogenic murine cell line with an ability to form 
orthotopic and subcutaneous tumor in normal immunocompetent C57L/J mice [78-
80]. Evaluating EpCAM+ CSCs derived from Hepa1-6 in above mentioned 3 
different animal models exhibiting 3 distinct liver pathology (control=healthy, 
HFD=steatosis, and NASH=steatohepatitis respectively) allowed us to 
systematically evaluate the tumorigenic capability of hepatocellular carcinoma 
CSCs in different immunocompetent liver microenvironments. For these 
experiments, we generated copGFP expressing stable Hepa1-6 cell line by 
lentivirus transduction. Unlike hind limb flank models where tumor growth can be 
monitored visually and/or by using Vernier calipers, orthotopic tumor growth 
required sensitive non-invasive imaging modality. Therefore, to monitor orthotopic 
tumor growth in liver of animal non-invasively, we utilized high-frequency 
ultrasound imaging using Visualsonics Vevo2100 instrument.  
As shown in figure 4.4-A, we first performed fluorescence assisted cell 
sorting (FACS) to obtain EpCAM+(positive) or EpCAM- (negative) subpopulation 
of Hepa1-6 cells with high copGFP expression. Animals in all 3 experimental 
groups (control, HFD, and NASH) were then randomly divided into 2 sub-groups 
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to receive orthotopic implantation of either EpCAM+ or EpCAM- cells (n=4 
mice/sub-group). Baseline ultrasound data recorded day before surgery. Total 2 
million (2x10^6) sorted copGFP expressing Hepa1-6 cells were then orthotopically 
injected into left liver lobes of animals by survival surgery (figure 4.4-B). Animals 
were followed up by ultrasound imaging to track tumor growth and euthanized at 
appropriate time. Simplified experimental workflow is shown in figure 4.4-C.  
 Neither control nor HFD group animals showed any tumor initiation or 
growth by high-frequency ultrasound imaging. Both EpCAM+ and EpCAM- Hepa1-
6 cells failed to initiate tumor in healthy liver microenvironment and mild steatosis. 
We followed animals for total 60 days by high-frequency ultrasound and 
euthanized them.  Gross liver analysis and dissection couldn’t confirm any tumors, 
and pathological analysis by H&E staining of injected lobes and adjacent lobes did 
not detect any microscopic tumors (Table 4.1).  
Table 4.1: Experimental outcomes of orthotopic implantation of EpCAM 










(10% Kcal from fat) 
EpCAM +/+ 4 0/4 
EpCAM -/- 4 0/4 
High Fat Diet  
(60% Kcal from fat) 
EpCAM +/+ 4 0/4 
EpCAM -/- 4 0/4 
NASH Diet  
(MCD + 60%  Kcal from fat) 
(n=3 separate experiments) 
EpCAM +/+ 11 10/11 
EpCAM -/- 10 2/10 
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NASH group of animals with EpCAM+ CSCs injection were confirmed tumor 
initiation as early as Day 5. On Day 13, detected tumors had grown larger while no 
tumors were detected in EpCAM-ve injection group of NASH animals (Figure 4.5-
A). All NASH animals were euthanized on Day 18.  Only EpCAM+ cells in NASH 
group had initiated tumors in almost all animals (10/11) (Table-4.1).  
Pathological analysis of NASH animals by HE staining confirmed the tumors, 
detected by high-frequency ultrasound analysis, in all 10 /11 EpCAM+ animals in 
NASH group.  IHC-P analysis confirmed significantly higher EpCAM expression 
compared to non-tumor EpCAM- animals (Figure 4.5-B). IHC-P analysis further 
confirmed expression of vimentin in EpCAM+ NASH tumors (Figure 4.5-B).  
Vimentin is a marker of epithelial to mesenchymal transition (EMT), suggesting 
that peripheral tumor cells acquired possible EMT properties which potentially 
helped spread of tumors and likely to be responsible for rapid growth in NASH liver 
microenvironment (Figure 4.5-B).  
 We injected copGFP expressing stable Hepa1-6 cells for the purpose of 
lineage tracking in vivo, to understand tumor growth. We performed 
immunofluoroscence analysis of frozen section (IHC-Fz) section of tumor tissue, 
and confirmed that the co-expression of EpCAM and copGFP (Figure-4.6).   
To confirm tumorigenic potential of EpCAM+ CSCs in control liver 
microenvironment of C57L/J mouse, we repeated the experiment with only control 
animals but with increased number of sorted EpCAM+ or EpCAM- cells injection , 
5 million instead of 2 million (data not shown).  HCC tumorigenesis experiment 
using control-healthy liver with 5 million cells injection found tumor confirmation in 
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3/3 animals in EpCAM+ group and 2/3 animals in EpCAM- group, with non-
significant difference in tumor size, after 18 days.  These tumors were small in size 
(1-2 mm in diameter). This repeated experiment confirmed that significant growth 
in NASH animals were contributed by steatohepatic microenvironment.  
In NASH group experiments, there were a few inexplicable results observed. 
In EpCAM+ group animals, histology analysis found a few tumors with either 
copGFP or EpCAM expression, but not both. This observation cannot rule out the 
possibility for transformation of host cells. Similarly, 2/10 animals in EpCAM-ve 
group had shown tumor growth, suggesting either experimental error or actual 
growth of EpCAM-ve cells which contributed to HCC initiation within NASH 
microenvironment. To answer these unanswered questions, we performed lineage 




Figure 4.4:  Orthotopic implantation of EpCAM expressing CSCs in mice: (A) 
Lentivirus transfected Hepa1-6 cells expressing copGFP were sorted by flow cytometry 
for EpCAM-/- and EpCAM+/+ populations; (B) Representative step by step surgical 
procedure – two million (2 x 10^6) sorted cells were injected into left liver lobe of C57L/J 












Figure 4.5:  EpCAM expressing CSCs in orthotopic NASH mouse model: 2 million 
sorted cells were injected into left liver lobe of C57L/J diet induced NASH mice by survival 
surgery, and tumor growth was monitored. (A) Non-invasive ultrasound images recorded 
at different time-points to track tumor progression in EpCAM-/- and EpCAM +/+ groups. 
(B) Visual observation of livers of euthanized mice on Day 18, and representative IHC-P 







Figure 4.6:  IHC-Fz staining of tumor from EpCAM+ CSCs in orthotopic NASH 
mouse model:  ICC confirmed that tumor arising from copGFP expressing EpCAM+ 
CSCs in NASH animals. Green fluorescence was natural fluorescence from copGFP. 
EpCAM was detected by Rabbit-Anti-EpCAM (1:100) followed by secondary signal 
amplification using Goat-Anti-Rabbit (1:500, Alexafluor – 594). FITC channel was used 
for detecting copGFP and TXRED channel used for detecting EpCAM. DAPI stain for 
nuclei was detected by UV channel filter.  Upper panel showed individual images and 




4.2) EpCAM+ve CSCs (copGFP tagged) are contributing to tumor initiation and 
not EpCAM-ve (mCherry tagged). 
We designed lineage tracking study with the objective to (1) identify the 
source of tumor initiation in orthotopic immunocompetent NASH microenvironment, 
and (2) systematically evaluate potential contribution of EpCAM+ and EpCAM- 
Hepa1-6 cells, and host liver cells in tumorigenesis.  For this experiment, in 
addition to two groups injected with either 2x106  EpCAM+ or EpCAM- Hepa1-6 
cells alone (stably expressing copGFP), we introduced a third group defined as 
“mixed group” with 50/50 ratio of EpCAM+/EpCAM- Hepa1-6 cells (Figure 4.7–A).  
In the “mixed group” NASH animals, 1x106 EpCAM+ cells stably expressing 
copGFP and 1x106 EpCAM- Hepa1-6 cells stably expressing mCherry, were mixed 
and injected into left liver lobes of animals by orthotopic injection procedure 
established for earlier experiments.   
Tumor growth was observed and recorded non-invasively with high-
frequency ultrasound imaging. All animals were euthanized on Day 18 post 
injection. Tumor incidence and tumor burden were found to be dose dependent on 
the numbers of injected EpCAM+ Hepa1-6 cells (Figure 4.7-B).  EpCAM+ group 
(100% EpCAM+ CSCs) showed significant higher liver weight (6.86±0.42 g, 
p=0.002), followed by mixed group with 50% EpCAM+ CSCs (5.00±0.73 g), and 
lowest in EpCAM- group with 0% CSCs, (3.13±0.59 g) (Figure 4.7-C, upper box 
plot). Similarly, tumor weight were significantly higher in EpCAM+ group 
(4.56±0.42 g, p<0.001), followed by mixed group with 50% EpCAM+ CSCs 
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(2.77±0.69 g), and least in EpCAM- group with 0% CSCs, (0.8±0.50 g) (Figure 4.7-
C, lower box plot).  
Mixed group’s tumors were of the highest interest for us, because these 
tumors were initiated from 50/50 mixture of copGFP expressing EpCAM+ CSCs 
and mCherry expressing EpCAM- non-CSCs (Hepa1-6 cells). Therefore, we could 
track the tumor lineage in vivo. As shown in figure 4.8-A, majority of tumor growth 
was contributed by EpCAM+ cells (high copGFP expression). Two tumors from 
different animals were analyzed by IHC-Fz analysis.  Tumor # 2 showed a faint 
expression of mCherry, but not significant, thus suggesting EpCAM+ cells 
(copGFP expression) dominated growth within tumor microenvironment over 
EpCAM- cells (mCherry). We confirmed the copGFP expression by IHC-P analysis, 
as shown in figure 4.8-B. Left “control” slide was performed to rule out non-specific 
antibody interaction (only secondary polymer incubated followed by DAB color 
development). Finally, we confirmed the expression with Western Blot analysis 
(Figure 4.8-C). We only observed copGFP expression in the mixed group and 
EpCAM+ groups, but not in the EpCAM- group. Similarly, no expression was 
detected for mCherry in the mixed group.  
Taken together, we have demonstrated that EpCAM+ Hepa1-6 CSCs 







Figure 4.7:  Tumor initiation in NASH liver microenvironment is dose dependent 
on intial EpCAM+ CSCs:  NASH group mice were orthotopically injected with 2 million 
Hepa1-6 cells. (A) Table showing experimental scheme of 3 groups, expected and 
observed results. (B) Representative gross liver pictures with tumor burden for each of 
the 3 group of NASH mice. (C) Box plot showing whole liver weight, (D) Box plot showing 
tumor weight, for each experimental group. EpCAM+ group (100% EpCAM+ CSCs) 
showed significant higher liver weight (6.86±0.42 g, p=0.002) and tumor weight 
(4.56±0.42 g, p<0.001), followed by mix group with 50% EpCAM+ CSCs (Liver: 
5.00±0.73 g, and tumor: 2.77±0.69 g), and lowest in EpCAM- group with 0% CSCs, 
(Liver: 3.13±0.59 g, and tumor: 0.8±0.50 g). Solid line in box plot represent median and 
dotted line represent arithmetic mean of each groups.  Significance was calculated by 





Figure 4.8:  Lineage tracking confirmed EpCAM+ CSCs (copGFP) contribute to 
tumor initiation in NASH immunocompetent microenvironment. (A) IHC-Fz 
staining and analysis of two different tumors from the mixed group (50:50 , 
EpCAM+:EpCAM-) in orthotopic NASH mouse model. Majority of tumors showed with 
green fluorescence (copGFP tagged EpCAM+ CSCs), while only very minute fraction of 
tumor showed red fluorescence in tumor # 2 (mCherry tagged EpCAM- non-CSCs).   (B) 
IHC-P staining confirmed copGFP expression using anti-copGFP antibody staining with 
secondary DAB color development with HRP-polymer. (C) Western Blot analysis 
confirmed copGFP expression from tumors of the mixed group and EpCAM+ group while 





4.3) EpCAM-High Hep3B cells showed tumor initiation property and aggressive 
tumor growth in liver microenvironment of Nu/J nude mice. 
Hep3B is EpCAM+ human cell line with hepatitis B virus integrated into its 
genome but not infective or actively propagating [81]. Hep3B is a well studied HCC 
cell line for orthotopic liver microenvironment which show characteristics of human 
HCC with detectable plasma levels of AFP in BALB/C nude mice [113]. However, 
none of the previous studies tested property of Hep3B cells with different degree 
of EpCAM expression using orthotopic nude mice model. Therefore, we 
systematically studied the ability of EpCAM-Low and EpCAM-High CSCs in 
orthotopic liver microenvironment of Nu/J athymic mice.  
Stable copGFP expressing Hep3B cell line was established with lentivirus 
transduction for the purpose of potential in vivo lineage tracking. 2 million EpCAM-
Low or EpCAM-High Hep3B cells were sorted by FACS and injected into left liver 
lobes of 10 week old athymic Nu/J nude mice by survival surgery as explained 
earlier (n=4 mice/group, two groups = EpCAM-Low and EpCAM-High). Tumor 
growth was monitored using non-invasive ultrasound imaging, and first tumor was 
detected on Day 35 in EpCAM-High group (data not shown). Mice were followed 
for 70 days and euthanized (none of the mice died in either group). 
At the end of 70 days from the Hep3B injection, 4/4 EpCAM-High group 
confirmed very high tumor growth while only 1/4 EpCAM-low group confirmed 
tumor (significantly lower in tumor size and volume compared with EpCAM-High 
group tumors). As shown in figure 4.9–A, gross liver observation and H&E staining 
confirmed presence of tumor in EpCAM-High group of animals. EpCAM-High 
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group of animals showed significantly higher tumor volume (2451.25±443.34 g, 
p=0.013, n=4 mice/group) and significantly higher liver weight (4.375±0.7 g, 
p=0.023, n=4 mice/group) compared to EpCAM-Low group of animals (tumor 
volume: 282.22±282 g, liver weight:1.7±0.1 g) (Figure 4.9-B).  We further analyzed 
expression of β-catenin, EpCAM, and copGFP. As shown in figure 4.9-C, EpCAM-
High group tumors confirmed copGFP expression suggesting tumors were initiated 
from the injected EpCAM cells.  Increased levels of EpCAM and β-catenin in 
EpCAM-High group suggest that EpCAM-high Hep3B cells preserved their 
expression and properties in vivo within liver microenvironment and were 
responsible for tumor initiation. Absence of tumor and copGFP/EpCAM expression 
in EpCAM-low group suggest that Hep3B cells with lower EpCAM expression 
inherently possess lower tumor initiation capability in vivo. 
Taken together, our Hep3B – Nu/J mouse model data suggest, for the very 
first time, that tumor initiation observed by Hep3B were primarily contributed by 
EpCAM expressing CSCs, especially EpCAM-high CSCs.  Also, these EpCAM-
High and EpCAM-low Hep3B cells did not change/alter their EpCAM expression 
profile and/or tumor initiating property in vivo post injection. For the first time, we 
have demonstrated that, without genetic alteration, spectrum of EpCAM 
expression on Hep3B cells possess distinct tumor initiating capability, and thus 






Figure 4.9:  EpCAM-High Hep3B subset possess tumorigenic potential in 
orthotopic Nu/J mouse model:  2 million sorted EpCAM-low or EpCAM-high Hep3B 
cells with constitutive copGFP expression were injected into left liver lobe of athymic 
Nu/J nude mice with survival surgery, and tumor growth was monitored for 70 Days. (A) 
Gross liver and HE stain of EpCAM-low and EpCAM-High animals.  All 4/4 animals in 
EpCAM-high group confirmed tumor by HE staining, while only 1/4 animals in EpCAM-
low group showed minor tumor in injection lob. (B) EpCAM-high group showed significant 
higher tumor volume and liver weight compared with EpCAM-low groups.  (C)Western 
blot analysis showed that EpCAM-high group animals/tumors show significant higher β-
catenin and concomitant EpCAM expression, with copGFP co-expression. Bar graphs 
show densitometric analysis of β-catenin (*p<0.05) and EpCAM (**p<0.001). GAPDH is 




4.4) Liver microenvironment promotes HepG2 mediated tumorigenesis in 
orthotopic athymic nude mice (Nu/J).   
HepG2 is another EpCAM+ human cell line with characteristics of human 
HCC [81]. ATCC have showed that HepG2 is non-tumorigenic cell line, while a few 
studies have found that HepG2 can initiate tumor in nude and SCID mice [50]. 
HepG2 is unique HCC cell line, correlated with high Wnt/β-catenin HCC subtype 
in clinic due to somatic mutation leading to a truncated β-catenin which is 
constitutively active [114, 115].  As EpCAM expression is regulated by Wnt/β-
catenin pathway, fate of HepG2 cell line in orthotopic liver microenvironment could 
be very distinct from that of Hepa1-6 and Hep3B cell lines.  
We established stable copGFP expressing HepG2 cell line, and sorted 
these cells for EpCAM-Low and EpCAM-High subgroups, similar to Hep3B study. 
FACS sorted 2 million cells were then injected into orthotopic Nu/J mice left liver 
lobes and established two groups (n=4 mice/group, EpCAM High and EpCAM 
Low). Animals were observed for tumor development by non-invasive ultrasound.  
We found the detectable tumors on day 30, in both EpCAM high and 
EpCAM low group animals. We followed tumor growth for 70 days, and animals 
were euthanized. As showed in figure 4.10-A, all mice in both EpCAM-High and 
EpCAM-Low group confirmed presence of tumors by observing gross liver and HE 
histology analysis. No significant differences were observed in liver weight and 
tumor volume between these two groups (Figure 4.10–B). Orthotopic tumors were 
observed with high necrotic regions and soft fluid filled regions. As explained 
earlier, HepG2 cell line possess mutant β-catenin which is constitutively active, 
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therefore tumorigenesis in EpCAM-Low group could explain the outcome with a 
rationale of higher β-catenin tumorigenic downstream activity.  
Interestingly, metastatic HCC occurred in 2/4 EpCAM-High animals (Figure 
4.11), and we confirmed presence of tumors by H&E histology analysis. In one 
mouse, tumor was observed near to bladder (overlapping with bladder tissue and 
connecting tissues), and in the second mouse, we found two distinct metastatic 
tumors in right kidney and pancreas respectively (Figure 4.11). These results were 
surprising to us because HepG2 cells have not been reported as a metastatic cell 
line.  
Taken together, we have shown that tumor initiation capability of HepG2 
cells were not significantly affected by EpCAM expression in vivo in orthotopic liver 
microenvironment. However, EpCAM-High HepG2 cells acquired metastatic 
abilities, suggesting EpCAM’s unique role in tumorigenesis despite constitutively 








Figure 4.10:  HepG2 EpCAM-Low and EpCAM-High HepG2 cell’s fate in 
orthotopic Nu/J mouse model of HCC:  2 million sorted EpCAM-low or EpCAM-high 
HepG2 cells with constitutive copGFP expression were injected into left liver lobe of 
athymic Nu/J nude mice with survival surgery, and tumor growth was monitored for 70 
Days. (A) Gross liver and HE staining of EpCAM-Low and EpCAM-High animals.  All 4/4 
animals in EpCAM-Low and EpCAM-High group confirmed tumor by H&E staining. (B) 
There was no significant difference observed in liver weight and/or tumor volume 










Figure 4.11:  EpCAM-High HepG2 cells metastasize in orthotopic athymic Nu/J 
mouse model:  Two of the four animals showed metastasis of HepG2. In the first animal, 
metastasis was observed near bladder, and second animal showed metastasis in Kidney 
and Pancreas.  Lower panel shown H&E staining of metastatic tissues, confirming 





We established different mouse models representing 3 distinct diet induced 
liver microenvironments i.e. healthy (control), steatosis (HFD), and inflammatory 
steatohepatitis (NASH). Then, we systematically studied tumorigenic abilities of 
EpCAM+ CSCs and EpCAM- Hepa1-6 cells in livers of animals, injected 
orthotopically. Tumor growth was accurately monitored by non-invasive high-
frequency ultrasound imaging. Control and HFD group of animals failed to initiate 
tumor following 2 million Hepa1-6 EpCAM+ cells, suggesting healthy liver and mild 
steatosis liver microenvironment rejected EpCAM+ CSCs. In NASH 
microenvironment, EpCAM+ CSCs showed aggressive tumor growth while 
EpCAM- Hepa1-6 cells demonstrated incidental tumor initiation (2/10 mice with 
tumors, much smaller in size and volume compared to EpCAM+ tumor).   We 
next performed lineage tracking studies to identify source of tumor initiation in 
NASH microenvironment. For this objective, we established constitutive copGFP 
expressing EpCAM+ CSCs and mCherry expressing EpCAM- cells. Our findings 
in lineage tracking studies showed that HCC initiation in C57L/J NASH mice was 
predominantly from EpCAM+ CSCs and not from EpCAM- Hepa1-6 cells.   
Next, we evaluated two human EpCAM+ cell lines (Hep3B and HepG2). We 
sorted EpCAM-Low and EpCAM-High Hep3B cells and injected them into liver 
lobes of Nu/J mice orthotopically. EpCAM-High group confirmed all 4/4 mice with 
aggressive tumor growth, while EpCAM-Low group showed only 1/4 mouse with 
successful tumor initiation (tumor in EpCAM-Low group is significantly smaller 
compared to EpCAM-High group). Western Blot analysis confirmed that 
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expression of β-catenin was significantly high in Hep3B tumors derived from 
EpCAM-High group compared to EpCAM-Low liver/tumor tissues. Our results 
demonstrate that EpCAM expression of Hep3B dictated tumor initiation capability 
in liver microenvironment.  
Similarly, we tested HepG2 tumorigenic property in orthotopic Nu/J mouse 
model. We sorted EpCAM-Low and EpCAM-High HepG2 subsets, and injected 
them into liver lobes of Nu/J mice orthotopically. HepG2 experiments 
demonstrated successful tumor initiation in livers of both EpCAM-High and 
EpCAM-Low group of animals. No significant differences were observed in tumor 
volume or liver weight between EpCAM-High and EpCAM-Low groups. HepG2 
cells have a constitutively active mutant β-catenin (~75 KD) which may explain 
failure to see differences in tumorigenesis in these experiments.  However, 2/4 
EpCAM-High animals confirmed metastasis to kidney and pancreas. Our results 
demonstrate that EpCAM expression of HepG2 cells did not affect its tumorigenic 
abilities, but potentially facilitate metastasis in liver microenvironment. 
Overall, our extensive and comprehensive in vivo study confirmed that 
higher tumorigenic capabilities were characteristic of EpCAM expressing CSCs in 
immunocompetent and immunocompromised liver microenvironment.  As EpCAM 
is a proposed target of Wnt/β-catenin, we next studied the role of Wnt/β-catenin 













Canonical Wnt/β-catenin pathway is well implicated in HCC [64]. Indeed, 
analysis of NIH-NCI’s cancer genome atlas identified CTNNB1 (β-catenin) as the 
3rd most mutated gene after TP53 in the HCC patients.  In Chapter 3, we found 
that β-catenin was upregulated in Hepa1-6 and HepG2 CSC spheroids.  Our 
findings suggest that β-catenin could be playing a critical role in the activation of 
CSCs or enrichment of CSCs in spheroids. Our systematic study in orthotopic 
animal models (Chapter 4) suggest that EpCAM+ CSCs inherent tumorigenic 
property in liver microenvironment. Extensive studies by Yamashita et.al. 
established EpCAM as CSC marker in HCC and also found that EpCAM is the 
target of Wnt/ β-catenin pathway in HCC CSCs and liver cancer [38, 95].  In colon 
cancer cell lines, β-catenin contribute to form colonospheres in vitro, an important 
characteristic of CSCs [87]. However, how β-catenin contributes to HCC CSCs 
activation is not yet known. Hence, here we evaluated canonical Wnt/β-catenin 
pathway to identify CSC activation event contributing to enrichment of CSCs 




5.1) Analysis of human specimens found significant higher EpCAM 
expressions in HCC tissues:      
Total protein was extracted from 8 pairs of malignant tissues and adjacent 
benign tissues.  Western Blot analysis was performed to analyze the EpCAM and 
β-catenin expression in these tissues (Figure 5.1-A & B). In 4 paired tissues, 
EpCAM expression was higher in malignant tissues compared to the benign 
adjacent tissues (samples 1, 2, 5, and 6). In 3 paired tissues, EpCAM expression 
was only slightly increased in malignant tissues compared to the benign adjacent 
tissues (samples 3, 4, and 8). However, in one pair (sample 7), EpCAM expression 
remained unchanged. β-catenin expression levels were found to be high in 5 
paired samples (samples 1, 2, 4, 5, and 6).  However, in pair 3, pair 7 and pair 8, 
β-catenin expression levels were found to be lower in malignant tissues compared 
to benign adjacent tissues. 
We have also examined 24 pairs of HCC tissues and adjacent benign 
control by IHC (Figure 5.1-C). Our data showed a significantly higher expression 
of EpCAM in specimens with HCC (483.75 ± 119.92, p<0.0001) when compared 






Figure 5.1:  Analysis of human HCC specimens. Total proteins were extracted from 8 
pairs of human HCC specimens (tumor tissue and adjacent benign tissue) and analyzed 
SDS-PAGE followed by Western Blot for EpCAM and β-catenin expression.  (A) Western 
blot; (B) densitometry image analysis of EpCAM (left) and β-catenin (right) expression in 
malignant tumor tissue and adjacent benign tissue (n=8). T: tumor tissue; B: benign adjacent 
tissue. Total 24 pairs of HCC specimens were analyzed by IHC staining. (C) Left: 
Representative images of IHC EpCAM staining of human tissue specimens. Right: 
Quantified EpCAM expression (n=24, paired benign AD and HCC specimens). 40X 






5.2) Gene expression analysis revealed Wnt/β-catenin upregulation induce 
potential dedifferentiation in Hepa1-6 CSCs  
Concomitant expression of EpCAM and β-catenin in HCC patients (Figure 
5.1) suggested β-catenin dependent tumorigenesis process during HCC 
development. Role of β-catenin in HCC development and EpCAM+ CSC activation 
is well established [62, 95].  Hence, we were intrigued to identify the source of 
EpCAM+ CSCs in Hepa1-6 spheroids. We hypothesized that EpCAM+ CSCs were 
enriching via Wnt/β-catenin dependent dedifferentiation of Hepa1-6 HCC cells.  
In order to test our hypothesis, Hepa1-6 control and spheroids were grown 
and harvested on Days1, 3, 5, and 7 to extract total RNA. Gene expression for β-
catenin, canonical Wnt pathway components (Wnt3a, Notum, Lrp5, Lrp6, GSK3β), 
HCC prognostic markers (EpCAM, AFP), Wnt independent stem cell activation 
markers (Lin28B, Sox2, Oct4) and EMT markers (E-Cadherin and Vimentin) were 
performed by qRT-PCR. All the results were analyzed by Pearson correlation 
analysis to identify linkage group genes regulated together.  
Figure 5.2 show heat-map gene analysis with correlation linkage of all the 
targets (left) and experimental groups (bottom). EpCAM and AFP expression were 
tightly regulated, as well as showed positive correlation with CD44 and CycD1 
(Wnt targets), vimentin, Notum (Wnt feedback inhibitor), β-catenin, Lrp5 and Lrp6 
(wnt co-receptors), and Lin28B (Wnt independent stem-cell marker). These data 
confirm previous findings in human HCC specimens (Figure 5.1) and are 
consistent with in vitro data for Hepa1-6 CSCs enrichment in spheroids, where we 
found upregulation of EpCAM. In addition to EpCAM, CSCs spheroids also showed 
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Lin28B upregulation in association with β-catenin and EpCAM. Lin28B is 
independent of β-catenin mediated regulation and a key protein in stem cell 
pathway, but also plays a role in tumorigenesis.  
Taken together, gene analysis data and Pearson correlation analysis 
suggested that CSC spheroids were enriched by potential dedifferentiation 














Figure 5.2:  Wnt/β-catenin upregulation induce potential dedifferentiation in 
Hepa1-6 CSCs:  Hepa1-6 control and spheroids were grown and harvested on D1, D3, 
D5, and D7 to extract total RNA. Gene expression for canonical Wnt pathway and 
dedifferentiation were analyzed by qRT-PCR. Heat-map showing gene analysis of all 
the experiments to identify genes which are related using Pearson correlation analysis.  
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5.3) Silencing β-catenin reversed CSCs properties  
Silencing β-catenin reverses spheroid phenotype of CSCs in EpCAM positive 
HCC cell lines.  
Upregulation of β-catenin led us to investigate the role of β-catenin in 
spontaneous generation of HCC CSC spheroids. Therefore, to further study 
implication of loss of function of β-catenin in spontaneous spheroid formation, we 
knocked down Ctnnb1 (β-catenin gene) using siRNA.  
Knockdown validation of Ctnnb1 (mouse) and CTNNB1 (human) were 
confirmed by Western Blot (Figure 5.2-A). We achieved >70% knockdown 
efficiency by siRNA mediated transfection. After 48-72 hours of Ctnnb1 knockdown 
(n=3 independent experiments), Hepa1-6 cells lost the spheroid phenotype and 
shifted to the differentiated phenotype, similar to their parent cells growing in the 
medium with serum (Figure-5.2-B).  This shifted phenotype of HCC spheroid was 
further confirmed in HepG2, a human EpCAM positive cell line. Upon CTNNB1 
knockdown by siRNA, HepG2 spheroids showed close to 98% reversal to 
differentiated phenotype in serum-free media (Figure 5.2-C). Loss of spheroid 
phenotype was more effective in HepG2 compared to Hepa1-6 upon the siRNA-




























Figure 5.3:  Silencing β-catenin expression reversed CSC spheroids phenotype. 
Hepa1-6 and HepG2 cells were grown in control or spheroid media for 4 days, transient 
transfection with scrambled siRNA control or siCTNNB1, followed by 48 to 72 hours 
incubation. (A) Western blot confirming ≥70% efficient knockdown. GAPDH used as positive 
control for transfection (n=3 independent experiments). (B) Hepa1-6; (C) HepG2 cells. 
Upper panels show average quantification (n=5 random fields/group) of spheroids (orange), 
adherent (blue), and single cells (green). Error bar is representing S.D. n=3 independent 
experiments, *** (p≤0.005, control), ### (p≤0.005, spheroids). Lower panel show visual 
representative images of corresponding experimental group. 
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Silencing β-catenin abolish drug resistance property of HCC CSCs  
Acquired resistance to chemotherapy contribute to minimal residual disease 
(MRD) after primary tumor treatment, and thus responsible for tumor recurrence.  
We investigated and confirmed in Chapter 1 that spheroid enrichment of CSCs in 
all 3 HCC cell lines acquired resistance to doxorubicin, a first line 
chemotherapeutic drug in HCC treatment. Transient knockdown of β-catenin by 
siRNA exhibited reversal of spheroid formation, a key CSC property as explained 
earlier in Chapter 5.3. Therefore, we sought to investigate if β-catenin knockdown 
also abolish HCC CSC‘s drug resistance property.  
Hep3B and HepG2 cells were grown in control or spheroid media for 3 days. 
On day 3, we performed transient transfection with scrambled siRNA control or 
siCTNNB1 with optimized conditions as established and validated for spheroid 
reversibility experiment (Figure 5.3-A). After 24 hours post transfection, (on day 4) ,  
we treated cells with 0.5 µM doxorubicin and incubated for additional 48 to 72 
hours, harvested and analyzed for viability by XTT assay. Hep3B spheroids with 
siCTNNB1 significantly lose doxorubicin resistance partially after 72 hours 
compared to siScrambled and doxorubicin alone (siCTNNB1+Dox: 0.38±0.032 , 
siScrambled+Dox: 0.51±0.48, Dox only:0.53±0.01, p<0.05, n=3 independent 
experiments).  Loss of doxorubicin resistance was also analyzed in HepG2 cells 
and found to be more apparent and drastic compared to Hep3B spheroids. In 
HepG2 spheroids, siCTNNB1 caused significant loss of doxorubicin resistance 
after 48 hours compared to siScrambled and doxorubicin alone (siCTNNB1+Dox: 
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0.35±0.01, siScrambled+Dox: 0.55±0.06, Dox only:0.51±0.025, p<0.005, n=3 
independent experiments).  
Additionally, in HepG2 cells, viability of siCTNNB1+Dox group was 
comparable to Control group after 48 hours (spheroids: siCTNNB1+Dox: 
0.35±0.01,  Control: siCTNNB1+Dox: 0.33±0.01). Thus suggesting that silencing 
β-catenin led to complete loss of acquired doxorubicin property of HepG2 CSCs. 
Notably, these findings in HepG2 cell line were consistent with complete 
reversibility observed after β-catenin knockdown (Figure 5.3-C).  
HepG2 is a unique HCC cell line, correlated with high Wnt/β-catenin HCC 
subtype in clinic due to a somatic mutation resulting in a constitutively active 
truncated β-catenin form (~75 KD) [114, 115].  Silencing β-catenin by siRNA 
decreased levels of full-length β-catenin (~92 KD), and truncated β-catenin in 
HepG2.  Also, HepG2 cell lines may have a higher turn-over of β-catenin. 
Overall, our data suggest that β-catenin serves as crucial player in 
activation and enrichment of HCC CSCs, and its silencing led to loss of CSC 
properties. Importantly, we provided first direct phenotypic evidence of spheroid 


























































































Figure 5.4:  Silencing of β-catenin abolished resistance to doxorubicin in HCC CSCs. 
Hep3B and HepG2 cells were grown in control or spheroid media for 3 days, transient 
transfection with scrambled siRNA control or siCTNNB1 on day 3, and treated for 0.5 µM 
Doxorubicin from day 4 to be followed by 48 to 72 hours incubation. (A) Hep3B spheroids 
showed significant loss of doxorubicin resistance after 72 hours compared with scrambled 
control (n=3 independent experiments, 2 different siRNAs targeting CTNNB1). (B) HepG2 
spheroids showed significant loss of doxorubicin resistance after 42 hours compared with 
scrambled control. Untreated (blue), Doxorubicin alone (red), Scrambled siRNA (green), and 
siCTNNB1 (purple). Error bar is representing S.D. n=3 independent experiments, ** p≤
0.005), * p≤0.05.  
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5.4) Regulation of HCC CSCs activation resides at nuclear level – study of 
Wnt/β-catenin pathway components by pharmacological inhibitors.  
Our results from Chapter 1 (Figure 1.12) identified increased levels of 
inactive GSK-3β phosphorylated at Ser9, suggested possible regulation at 
destruction level complex in the cytoplasm. In order to decipher exact point-of-
action for CSC activation mechanism we have systematically analyzed the Wnt/β-
catenin pathway with different chemical inhibitors (each targeting one step at a 
time). We selected 4 chemical inhibitors (LiCl, MG132, XAV939, and FH5355) for 
this objective after preliminary experiments (Figure 5.4). We determined optimal 
effective concentrations for each of the 3 HCC cell lines i.e. Hepa1-6, HepG2, and 
Hep3B after extensive preliminary experiments (data not shown). We used these 
optimum concentrations for further studies i.e. LiCl =10 mM , XAV939 = 10 µM, 
and FH535 = 10  µM.  MG132 was not used because of high apoptosis induction 
possibly because of non-specific accumulation of other cellular proteins. LiCl 
activates Wnt/ β-catenin signaling by inhibiting Ser9 phosphorylation of GSK-3β 
and thus stabilizing cytoplasmic pool of β-catenin.  XAV939 and FH535 inhibit 
Wnt/β-catenin pathway at cytoplasmic (destruction complex level) and nuclear 
transcriptional levels, respectively.  
Figure 5.4-B showed confirmation of functional effects by inhibitor treatment 
on Hepa1-6 cell line experiments. LiCl significantly increased β-catenin and 
EpCAM expression, while XAV939 induced degradation of β-catenin and 
decreased EpCAM expression.  
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We expected treatment with XAV939 and FH535 to produce similar results 
of spheroid reversibility as observed in Figure 5.3 after siRNA mediated β-catenin 
knockdown.  
As seen in Figure 5.6, CSC spheroid culture of all 3 HCC cell lines respond 
only to FH535 but not XAV939. These results suggest that destruction complex 
inhibition by XAV939 did not exhibit functional consequences on spheroid 
formation of CSCs, and thus CSC activation and/or spheroid activation regulation 
must be occurring downstream of GSK-3β dependent destruction complex 
regulation.  CSCs spheroids in all 3 cell lines responded to FH535 treatment and 
inhibition of spheroid formation were observed. Because we activated Wnt 
pathway with LiCl treatment simultaneously, plenty of stabilized β-catenin should 
be available for nuclear translocation and downstream gene activation at 
transcription levels. However, FH535 inhibits transcriptional level activity of β-
catenin in HCC CSCs, suggesting that regulation of CSC activation takes place at 
the nuclear level.   
Overall, we have identified the regulation switch of HCC CSC activation and 
spheroid formation, and it occurs at the nuclear level and not at the destruction 





















Figure 5.5:  Inhibitor study to identify control point of Wnt/β-catenin pathway during 
CSC activation. (A) Cartoon figure showing mechanism of action of chemical inhibitors 
used, with brief explanation of their mechanism of actions on right side. (B) ICC staining of 
Hepa1-6 cells: untreated control, treated with 10 mM LiCl and 10 µM XAV939.  EpCAM 
(Green, Alexafluor-488)), β-catenin (Red, Alexafluor-594), DAPI – nuclear (Blue), Control = 
untreated cells.  LiCl increased EpCAM-ICD and β-catenin expression while XAV939 
decreased EpCAM-ICD expression and direct β-catenin for ubiquitin mediated degradation 













Figure 5.6:  HCC CSC activation and spheroid formation is β-catenin dependent and 
regulated at the nuclear level. All 3 HCC cell lines were cultured in serum free media for 
7 days to generate CSCs spheroids. On day 8, cells were treated with LiCl alone, LiCl + 
XAV939, and LiCl + FH535 for 48 hours. After 48 hours, cells were observed by microscope 
and bright field images were captures. As showed in figure red box, XAV939 treatment was 
ineffective to revere or destroy spheroid formation. However, FH535 treatment was effective 
in all 3 cell lines to inhibit or reverse spheroid formation.  10x magnification, bar = 200 µm.  
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5.5) NOTUM inhibition feedback in Wnt/β-catenin pathway turned non-
responsive in EpCAM+ tumors of NASH mouse model and human HCC. 
Recently, Wnt/β-catenin feedback inhibitor NOTUM was deciphered [116]. 
NOTUM is target of Wnt/β-catenin signaling which deacylates Wnt to turn off the 
signaling. This feedback inhibition check point prevents accidental activation of 
Wnt signaling.  
We analyzed 5 human HCC tumors and adjacent tissues.  4/5 HCC 
specimens showed higher NOTUM expression compared to adjacent control 
(Figure 5.7-A). Similarly, IHC-P staining of tumors developed in EpCAM+ CSCs 
NASH group mice from Chapter 4, showed higher expression of both Wnt3a and 
NOTUM (Figure 5.7-B). Increased NOTUM expression in human and mouse 
tumors suggest that Wnt/β-catenin driven tumors failed to respond to NOTUM 
feedback inhibition. This makes sense because, as shown in Chapter 5-3, Wnt/β-
catenin signaling in HCC CSCs is not regulated at cytoplasmic destruction complex 
level but at the nuclear level.  
Taken together, NOTUM mediated feedback is ineffective to switch off 
upregulated Wnt/β-catenin signaling in HCC tumors. Nuclear level regulation of β-
catenin allows constitutive activation of downstream oncogenic targets, and as a 
result, one of the downstream targets, NOTUM, showed upregulation. However, 
since NOTUM mediated feedback inhibition required cytoplasmic signaling 
regulation, which is lacking in HCC CSCs, increase in NOTUM expression does 











Figure 5.7:  Aberrant NOTUM inhibition feedback in HCC patients and EpCAM+ CSCs 
NASH mice tumors. (A) 4/5 human HCC specimens showed increase NOTUM levels in 
tumor compared with adjacent. (B) Representative EpCAM+ CSC tumor from orthotopic 




We demonstrated that EpCAM and β-catenin are concomitantly increased 
or decreased in human HCC specimens compared to adjacent healthy controls.  
CSC spheroid enrichment gene analysis in Hepa1-6 revealed possible 
dedifferentiation events occurring during spheroid formation. Importantly, HCC and 
Wnt pathway genes are upregulated with spheroid enrichment, and Pearson 
correlation analysis linked them to stem cell activation genes (Lin28B, β-catenin). 
Loss of function study of β-catenin showed that properties of CSCs are lost upon 
transiently silencing β-catenin, (1) Hepa1-6 and HepG2 reversed CSC spheroids 
to adherent phenotype, (2) HepG2 and Hep3B EpCAM positive cell lines lost 
acquired doxorubicin resistance. Meticulous chemical inhibition of Wnt/β-catenin 
pathway components identified regulation of HCC CSCs activation resides at the 
nuclear level.  And lastly, recently identified canonical Wnt/β-catenin feedback 
inhibitor, NOTUM, showed increased expression in human and mouse NASH 
tumors. These findings suggest an important role of β-catenin in CSC mediated 
tumorigenesis. Importantly, our findings suggest that aberrant Wnt/β-catenin 
pathway activation in CSCs via nuclear level changes, made β-catenin driven HCC 










The existence of cancer stem cells (CSCs) is no longer a debatable topic 
since they have been definitively identified by three independent lineage tracking 
studies [41-43]. However, the origin of CSCs has not been elucidated and is still 
an active area of investigation [101, 117]. Primarily two arguments exist:(1) CSCs 
originate by dedifferentiation from either cancer cells or normal cells, and (2) CSCs 
originate by mutations and biochemical changes in tissue-specific pools of normal 
progenitor or stem-cell compartments [118-122]. A study by Yamanaka et.al. 
showed that terminally differentiated fibroblast cells possess reprogramming 
capabilities to go back to the pluripotent stem cell niche [123].  Considering 
unpredictable tumor cell fate and the poorly understood tumor microenvironment, 
the origin of CSCs from differentiated cancer cells seems a likely possibility [32, 
124].  
 Our results suggest that β-catenin plays a strategic role in switching from 
a differentiated cancer cell phenotype to a dedifferentiated CSC phenotype in HCC 
cell lines. Results from Chapter 3 demonstrated that both cytoplasmic and nuclear 
levels of β-catenin in HCC CSCs were significantly increased compared to 
adherent control, and these increased levels of β-catenin display functional effects 
on downstream targets i.e. increase in TCF1, LEF1, CycD1 expression. We also 
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found that increased levels of β-catenin and downstream dedifferentiation effects 
were regulated at destruction complex level, at least partially, which was confirmed 
by increase in inactive GSK3β levels (Ser9-phosphorylation).  Our findings in HCC 
spheroids are consistent with a study in colonosphere which showed aberrantly 
increased levels of β-catenin in spheroids compared to adherent cell lines [87].   
Surprisingly experiments in Chapter 5 where we systematically studied canonical 
Wnt/β-catenin by means of chemical inhibitors, revealed that inhibiting GSK3β by 
XAV939 failed to reverse HCC CSC spheroids. However, these CSC spheroids 
responded to nuclear level β-catenin transcription inhibition by FH535 and led to 
arrest in their growth.  Taken together, these findings suggested that nuclear 
regulation of β-catenin plays a fundamental role in CSC activation compared to 
cytoplasmic canonical Wnt/β-catenin regulation.  
Loss of β-catenin by siRNA confirmed and complemented results of the 
inhibitor, FH535, where upon β-catenin silencing HCC CSCs spheroids reversed 
to adherent phenotype and lost doxorubicin resistance. Indeed, siRNA 
experiments confirmed central role of β-catenin in regulation of CSC activation and 
ruled out possibility of β-catenin independent (non-canonical) Wnt signaling.  Loss 
of cytoplasmic regulation at destruction complex level (GSK3β level) suggested 
that stabilizing and translocating cytoplasmic β-catenin no longer serve as a rate 
limiting step for canonical Wnt pathway mediated HCC CSCs activation [125]. 
Mokkapati et al. showed that β-catenin activation alone in liver progenitor cells is 
sufficient to cause tumorigenesis in HCC [102]. This is further supported by studies 
in breast cancer and colon cancer [84, 87]. In breast cancer, targeting Wnt/β-
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catenin pathway has shown to chemosensitize CSCs [59, 60]. In head and neck 
cancers, Wnt antagonist was shown to chemosensitize CSCs [61]. Study by 
Hashimoto et.al. showed that dedifferentiated spheroid cells confer 
chemoresistance in HCC as shown in our preliminary studies [58]. Our results in 
Chapter 5 (β-catenin silencing by siRNA) also observed loss of acquired 
doxorubicin resistance upon β-catenin silencing, and consistent with current 
literature. Involvement of β-catenin strongly implies that the heterogeneous cancer 
cells in a tumor mass could be an important pool of cancer-cell progenitors or 
CSCs. These CSCs are enriched via β-catenin mediated transcription activation, 
and contributing to HCC recurrence via chemotherapy resistance and minimal 
residual disease.  
EpCAM correlates with poor HCC prognosis and downstream target of 
Wnt/β-catenin signaling [53, 95]. We further investigated specific EpCAM+ CSCs 
using orthotopic immunocompetent mouse model in 3 distinct liver 
microenvironments (Control, HFD, NASH). Hepa1-6 cell line was reported as a 
non-immunogenic murine cell line with an ability to form tumors in normal 
immunocompetent C57L/J mice, both orthotopically and subcutaneously [78-80], 
thus provide more clinically relevant mouse model to study tumorigenesis in 
presence of all immune system components, unlike athymic nude or SCID mouse 
models which lack an immune system.  
 In this dissertation project, we demonstrated that Wnt/β-catenin signaling 
plays a central regulatory role in HCC CSCs activation and enrichment in vitro.  
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We systematically studied in vivo fate of EpCAM+ CSCs of three different HCC 
cell lines in orthotropic models.   
 
The major findings of this dissertation  
Current and previous clinical trials targeting CSC activation pathway face 
challenges due to a lack of complete understanding of stemness plasticity [126]. 
Clinical trials rely on data obtained from pre-clinical rodent models, and majority of 
current CSCs knowledge was developed from athymic or SCID mice with hind limb 
xenografts [106].  There remains an unmet need to test and claim CSC properties 
in clinically relevant orthotopic rodent models.   
In this study, we tested CSCs derived from HCC cell lines in orthotopic liver 
mouse models.  Hepa1-6 is a murine HCC cell line closely representing poorly 
differentiated HCC growth in C57BL/6J and C57L/J mouse models [127, 128]. As 
explained in chapter 4, we have tested EpCAM+ Hepa1-6 CSCs in three different 
liver microenvironments i.e healthy controls, steatosis, and NASH. It has already 
been established that fatty liver progression exacerbate HCC carcinogenic events 
within liver microenvironment [109]. We have demonstrated that the NASH liver is 
favorable to EpCAM+ CSCs mediated tumorigenesis in immunocompetent 
microenvironment, while control and steatosis are not.  Importantly, our findings 
suggested that EpCAM+ CSCs could successfully evade host immune 
surveillance in the NASH liver microenvironment. Therefore, the NASH mouse 
model can be vital tool to study immune checkpoint therapies and immune 
surveillance in tumor immunology.  
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Hep3B cell line is p53 null with mesenchymal phenotype, slow growing, and 
demonstrate well differentiated HCC tumors in mouse model [81] [113]. Orthotopic 
evaluation of EpCAM-High and EpCAM-low subsets of Hep3B demonstrated that 
the degree of EpCAM expression, not merely its presence or absence, positively 
correlates with severity of tumorigenesis. Hep3B/Nu-J experiments provide 
glimpse into nature of EpCAM expressing CSCs that hierarchal EpCAM 
expression bears different tumor initiating capability. 
HepG2 cell line express a constitutively active form of β-catenin (truncated 
β-catenin, ~75 KD), but is considered as non-neoplastic hepatoma cell line [114, 
115]. However, only a few studies have been successful in tumor initiation in 
animal models [50, 129]. Therefore, we tested HepG2 EpCAM-High and EpCAM—
low subsets in orthotopic animal models, and found no significant differences in 
tumorigenesis potential. Considering constitutively active β-catenin status in 
HepG2 as explained above, distinct outcomes of HepG2/Nu-J experiments are not 
surprising. However, this study is first to report that the EpCAM-High HepG2 
subset possess metastatic ability.  Interestingly, HepG2/Nu-J experiments 
demonstrated that despite a constitutively active β-catenin, higher degree of 
EpCAM expression can steer these cells towards metastasis.  
In chapter 5, data demonstrated central role of β-catenin in spheroid 
enrichment and doxorubicin resistance. Using XAV939 and FH535 chemical 
inhibitors, we also deciphered that β-catenin mediated CSC activation is regulated 
at the nuclear level. Subsequent analysis in human and animal tissues showed 
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that NOTUM feedback regulation is disturbed, which could be a potential 
mechanism for uninhibited β-catenin driven tumors in vivo.   
 
 
Limitations of this dissertation 
This dissertation was focused on EpCAM expressing CSCs, regulated by 
Wnt/β-catenin signaling. All 3 HCC cell lines we chose are expressing EpCAM. To 
be specific, Hepa1-6 is heterogeneous cell line in terms of EpCAM expression, 
while both HepG2 and Hep3B are EpCAM positive cell lines. Other Wnt/β-catenin 
signaling mediated CSC targets such as CD44 and ABCG2 were not studied as 
extensively as EpCAM in this dissertation, therefore, interpretation of current work 
should not be applied for CD44+ CSCs and ABCG2+ CSCs.   
Future directions 
Experimental work in this dissertation identified critical role of β-catenin in 
CSC enrichment, and demonstrated that aberrant activation of β-catenin in CSCs 
is regulated at the nuclear level, at least partially. This aberrant activation of β-
catenin subsequently abolish NOTUM mediated feedback inhibition loop of the 
Wnt/β-catenin pathway.  Deciphering this puzzle of nuclear β-catenin transcription 
activation in CSCs in HCC should be pursued next.  
A few studies have shown direct nuclear activation of β-catenin mediated 
transcriptions. Study by Zhao et.al. identified YY1AP1 in EpCAM+AFP+ HCC, and 
proposed that both YY1PA1 and β-catenin contribute to EpCAM expression, which 
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however depends on p53 signaling status [50].  In another study, LEF1 protein, 
one of the nuclear interactive partners of β-catenin, is regulated by hepatocyte 
growth factor (HGF, paracrine) in breast and liver cancer cell lines [130]. A study 
by Li et.al. reported that TBL1-TBLR1 and β-catenin recruit each other to Wnt 
target-gene promoter and activate transcription [131]. Dimitrova et.al. identified 
that novel direct ubiquitination of  β-catenin by Siah-1 and TBL1 protected β-
catenin from degradation by competitive binding on the armadillo repeat domain 
of β-catenin [132]. Additionally, Choi et.al. suggested that SUMOylation of TBL1-
TBLR1 regulates β-catenin expression and activity.  
Orthotopic animal models that we developed could serve as more clinically 
relevant tools to study tumor immunology in HCC. Despite success of checkpoint 
inhibitors in other cancers, there isn’t a significant progress in HCC.  Our 
immunocompetent mouse model of NASH liver microenvironment (C57L/J) 
bearing EpCAM+ Hepa1-6 cells injected orthotopically in the left lobe, could serve 
as a system to understand how EpCAM+ cells evade host immune-surveillance in 
NASH (but failed to evade in healthy control and mild steatosis livers). Overall, our 
data with EpCAM expressing CSCs suggest that CSCs with other markers like 
CD90, CD44, and CD133 can also be systematically studied in similar 
immunocompetent models with orthotopic injections of CSCs instead of flank-






Concluding remarks  
This dissertation identified role of Wnt/β-catenin in activation of cancer stem 
cells in Hepatocellular carcinoma. These CSC spheroids acquired Doxorubicin 
resistance, and upon silencing β-catenin, there was not only a loss the spheroid 
phenotype, but also reversal to the adherent phenotype, and subsequent loss of 
resistance to doxorubicin.  HCC spheroids showed significantly higher tumorigenic 
abilities in orthotopic immunocompetent mouse models. We further tested fate of 
EpCAM+ CSCs in 3 different HCC cell lines, in more clinically relevant orthotropic 
mouse models. In immunocompetent mice, we demonstrated that EpCAM+ CSCs 
need NASH microenvironment to initiate HCC. Immunocompromised mice with 
Hep3B and HepG2 cells offered insights into effect of EpCAM expression on 
tumorigenesis. Gene analysis studies suggested that CSCs are capable of 
dedifferentiation mediated by the Wnt/β-catenin pathway.  We also demonstrated 
that activation of CSCs resides at the nuclear level as a result of gene transcription 
stimulated by β-catenin. Lastly, dysregulation of the canonical Wnt pathway in the 
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